Pancuronium and its metabolites: pharmacology, pharmacodynamics, pharmacokinetics and antagonism by Booij, L.H.D.J.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/148013
 
 
 
Please be advised that this information was generated on 2018-07-07 and may be subject to
change.
2.sfó 
Pancuronium and its 
pharmacology 
pharmacodynamics 
pharmacokinetics 
and 
antagonism 
L.H.D.J.Booij 
metabolites: 
0 to5 ; ¿ r P Ac CT Х ^ ^ ^ ^ 
0 2 ^ Р 
0bS*9 
cbSaP 

PANCURONIUM AND ITS METABOLITES: 
PHARMACOLOGY, PHARMACODYNAMICS, 
PHARMACOKINETICS AND ANTAGONISM 
PROMOTORES 
PROF DR J F CRUL 
PROF R D MILLER 
PANCURONIUM AND ITS METABOLITES: 
PHARMACOLOGY, PHARMACODYNAMICS, 
PHARMACOKINETICS AND ANTAGONISM 
PROEFSCHRIFT 
TER VERKRIJGING VAN DE GRAAD VAN DOCTOR IN DE 
GENEESKUNDE AAN DE KATHOLIEKE UNIVERSITEIT TE NIJMEGEN, 
OP GEZAG VAN DE RECTOR MAGNIFICUS 
PROF. DR. P. G. A. B. WIJDEVELD 
VOLGENS BESLUIT VAN HET COLLEGE VAN DECANEN 
IN HET OPENBAAR TE VERDEDIGEN OP DONDERDAG 
2 APRIL 1981 DES NAMIDDAG TE 4.00 UUR 
DOOR 
LEONARDUS HENRICUS DOMITIANUS JOSEPH BOOIJ 
GEBOREN TE DORDRECHT 
1981 
DRUKKERIJ-UITGEVERIJ BRAKKENSTEIN, 
NIJMEGEN 
Copyright 1981 L. H D. J. Booij 
No part of ibis thesis may be in any way reproduced 
without written permission of the author. 
In memory of my father 
For Ria, Josquin and Celesta 
"From early enthusiasm through temporary damnation, 
relaxants have progressed to a status of great respect 
and importance to all of medicine." 
- William K. Hamilton (1979) 
Professor and Chairman of 
Anesthesia, Universi ty of 
Ca l i forn ia , San Francisco, 
U.S.A. 
6. 
FOREWORD 
During general anesthesia, approximately 60 to 70 percent 
of all patients receive a nondepolarizing muscle relaxant. With 
the development of safer and more ideal relaxants, as well as the 
increased understanding of their mechanism of action, the admin-
istration of the relaxants by experienced anesthetists is without 
great risk. Nevertheless, Stanley A. Feldman made the following 
statement in 1980: 
"Although the neuromuscular blocking drugs are seldom 
the cause of overt mortality or morbidity, there is 
little doubt that residual paralysis in the recovery 
phase is a frequent cuase of uncomfortable and danger-
ous side effects." 
These uncomfortable and dangerous side effects have been 
observed in many cases where pancuronium has been administered. 
It has been suggested that the metabolism of pancuronium was 
the causative factor. This thesis is a collection of studies 
performed with the objective of demonstrating the safety of pan-
curonium, in spite of its metabolism. 
The kind co-operation and stimulation received from the mem-
bers of the Department of Anesthesiology of the Catholic Universi-
ty of Nijmegen were of great value in the preparation of this 
thesis. The help of the many people who contributed during the 
performance of the experiments, the search for literature, the 
drawing of the figures, and the discussions during the work meet-
ings is gratefully appreciated. Special acknowledgement is extend 
ed to the technical assistance received from Francien van der Pol 
and Wim Kleinhands during the studies. Carla Vermeulen generously 
edited and typed the manuscript. Dr. David S. Savage (Organon 
Ltd., Newhouse, Scotland) kindly provided me with the pancuronium 
derivatives. The members of the 'international muscle relaxant 
group' frequently showed their interest in our work, especially 
Dr. Ronald D. Miller, who was my main assessor. Last but not 
least, I thank Ria, Josqum, and Celesta for their patience and 
for their consideration during the work on this thesis and its 
many studies. 
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CHAPTER 1 
INTRODUCTION 
Muscle relaxation during general anesthesia is mainly achieved 
by neuromuscular transmission blocking agents. These are charac­
teristically either depolarizing or nondepolarizing. The depolar­
izing neuromuscular blocking agents show intrinsic activity on the 
acetylcholine receptors of the motor end-plate. The nondepolarizing 
blockers only compete with acetylcholine for the receptors but have 
no intrinsic activity. Pancuronium is presently the most frequently 
used nondepolarizing relaxant. Contrary to d-tubocurarine, meto-
curine and gallamine, pancuronium undergoes metabolism primarily in 
the liver (Agoston et al. 1973а'Ь; Buzello 1975). Some of the 
unexpected side effects and complications after the administration 
of pancuronium may therefore be related to the products of this 
metabolism. Other side effects and complications can be explained 
by interaction with other drugs such as antibiotics (Pittinger et 
al. 1970, 1972; Booi] et al. 1978; Rutten et al. 1981), local anes­
thetics (Telivuo et al. 1970), quinidine (Miller et al. 1967), 
ketamine (Johnston et al. 1974), furosemide (Miller et al. 1978a; 
Azar et al. 1980), inhalation anesthetics (Miller et al. 1971,1972; 
Ngai 1975), and Imipramine (Edwards et al. 1979). Other side 
effects are explainable by pre-existing disturbances in acid-base 
balance (Crul-Slui]ter et al. 1974; Miller et al. 1975), changes in 
temperature (Zaimis et al. 1958; Ham 1977; Miller et al. 1978b), 
and electrolyte shifts (Giesecke et al. 1968; Ghoneim et al. 1970), 
while still other side effects are the result of an action on other 
organ systems (Saxena et al. 1971; Nana et al. 1973; Domeneck et 
al. 1976; Kumar et al. 1978). 
Prolonged paralysis and problems in antagonizing the blockade 
by neostigmine and pyridostigmine are seen occasionally and are 
then poorly understood. This happens most usually after prolonged 
administration of pancuronium in patients with renal and/or hepatic 
diseases (Miller et al. 1976). Especially in these cases, impaired 
metabolism and cumulation of pancuronium and its metabolites are 
suggested. It is a great lack that the amount and time course of 
metabolism is not exactly known because of lack of a specific quan­
titative method of separation and analysis of pancuronium and its 
metabolites. With aspecific semiquantitative methods (Kersten et 
al. 1973), total metabolism is estimated to be 30-45%. 25-35% of 
the pancuronium is metabolized into 3-OH-pancuronium and 5-10% into 
17-OH and 3,17-diOH-pancuronium together (fig. 1). 
The main excretion is through the kidneys, while during renal 
failure the liver can partially compensate for this by increased 
uptake (Agoston et al. 1977). 
On a theoretical basis, problems may occur if the pancuronium 
metabolites also possess neuromuscular blocking properties. Accumu­
lation of metabolites may then contribute to the blockade. The 
pharmacodynamics and pharmacokinetics of the metabolites are there­
fore important. Problems can also occur if active metabolites are 
less reversible by acetylcholinesterase inhibitors, or if they 
interact with each other and pancuronium in a synergistic way, i.e. 
potentiate each other. A study of the pharmacology, pharmacodyna­
mics, pharmacokinetics and antagonism of pancuronium and its meta-
11. 
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Figure 1. Strurtural formulas for pancur­
onium and its metabolites. 
bolites xs therefore of great clinical importance. 
To overcome the problem of the lack of a specific assay, we 
studied pancuronium and its metabolites when administered separately 
both in man and in animals. 
Although we recognize that with all these compounds (except in 
the case of 3,17-diOH-pancuronium) metabolism will take place, and 
that conclusions drawn are not absolute, it was presumed that the 
compounds when administered individually were not broken down to a 
major degree during the time course of the experiment. The concen­
tration of compound measured by a fluorimetrie method (Kersten et 
al. 1973) was thereby considered to be that of the compound injected. 
We realize the limitation of this presumption, but believe this to 
be the only method presently available for investigation of the 
influence of the metabolism of pancuronium. Only when the 3,17-
diOH-denvative is used will no further metabolism take place, thus, 
conclusions drawn from this drug are not valid. Since the behavior 
of the other two metabolites is analogous to that of 3,17-diOH-pan-
curomum, the presumption made earlier is acceptable. 
In the following chapters, the role of the pancuronium metabo­
lites and their action and reversal are discussed. In these 
chapters, many different species were studied using various tech­
niques. This was necessary since for ethical reasons some of the 
studies could not be performed in man. Either in vitro or in vivo 
studies were performed, the choice being based upon technical 
appropriateness. 
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CHAPTER 2 
METABOLISM, PHARMACODYNAMICS AND PHARMACOKINETICS OF PANCURONIUM, 
A REVIEW OF THE LITERATURE 
Since many drugs bearing acetyl groups are metabolized by 
esterase activity to hydroxy1 groups, it was assumed that pancuron­
ium is also converted to corresponding hydroxyl analogues. There 
were three metabolites possible: 3-OH-pancuronium, 17-OH-pancuron-
lum, and 3,17-diOH-pancuronium. By combined thin layer chromato­
graphy and fluonmetry (Kersten et al. 1973), all three metabolites 
are indeed demonstrated in animals and in man (Agoston et al. 
1973а'ь; Buzello 1975). 
Estimations for the amount of metabolism are made from the 
analysis of plasma, urine, and bile. 35-45% of the injected pancur­
onium is thought to be metabolized: 30-35% into 3-OH-pancuronium, 
and 5-10% into 17-OH-pancuronium and 3,17-diOH-pancuronium together 
(Agoston et al. 1973а<Ь; Buzello 1975). Of the possible metabolites, 
17-OH-pancuronium possesses 1/50 the potency of pancuronium in 
blocking the neuromuscular transmission (Feldman et al. 1970; Norman 
et al. 1971). No data could be found in the literature for the 
other compounds. On intravenous injection, pancuronium exerts its 
maximal effect within 2-8 minutes (Dobkin et al. 1971, Katz 1971). 
95% depression of twitch response is caused by pancuronium 0.0625 
mg/kg body weight (Somogyi et al. 1978; Krieg et al. 1980). In 
most cases, complete blockade is observed with 0.08 mg/kg, which in 
patients without renal or hepatic diseases is recovered to 10% of 
the control in about 65 minutes (Katz 1971) . Five minutes after 
injection, 60% of the injected amount has disappeared from the 
plasma, 80% after 30 minutes, and 90% after 1 hour, resulting in 
half-life tunes in the distribution phase (t^a) of 4-10 minutes, 
and in the elimination phase (t^$) of 108-147 minutes (Agoston et 
al. 1973b). After 30 hours 43% is excreted in the urine and 11% m 
the bile. It is assumed that liver uptake plays an important role 
in termination of the pancuronium activity (Agoston et al. 1977a). 
Pharmacokinetic models have been developed for pancuronium both as 
2- and 3-compartjnent open models (MacLeod et al. 1976; Somogyi et 
al. 1976; Hull et al. 1978; Buzello et al. 1978). 
In patients with renal failure, the duration of the blockade 
is prolonged by 50% (Miller et al. 1973), but the intensity of the 
blockade is not different. This is explained by decreased plasma 
clearance, and longer t'ja and t%ß (Somogyi et al. 1977a). Conse-
quently, there is a decrease in pancuronium elimination (MacLeod 
et al. 1976), and thus a higher plasma level during the elimination 
phase. After the first injection, the depots are not yet filled 
up, and since the duration of blockade is largely dependent on re-
distribution of the relaxant, the duration is not significantly 
prolonged. With each subsequent repeating dose, the duration of 
blockade is prolonged because less redistribution can then occur. 
With total biliary obstruction, t^B is prolonged and plasma 
clearance decreased, leading to a longer duration of action 
(Somogyi et al. 197І^1 ) . In the case of cirrhosis of the liver, 
t^a and t^ g are significantly prolonged (Duvaldestin et al. 1978a). 
With cirrhosis of the liver, hyperhydration may be present as a 
15. 
result of a low plasma protein concentration. This in turn may on 
one hand cause a decreased central volume of distribution, and,on the 
other hand, result in less protein binding. Since 80% of the in­
jected pancuronium is normally bound to plasma proteins (Thompson 
1976), the plasma concentration of the unbound pancuronium may then 
be elevated. 
In hypothermia, a reduction in pancuronium requirement with 
prolonged duration has been shown in cats (Miller et al. 1977) . The 
reasons have been proven to be the decrease in urinary and biliary 
excretion, decrease in pancuronium metabolism, and increase in 
sensitivity of the neuromuscular junction (Miller et al. 1978) . 
There is a good correlation between percentage depression of 
the twitch and the plasma level of pancuronium, both after bolus 
injection and continuous infusion (Somogyi et al. 1976; Agoston et 
al. 1977b,· Shanks et al. 1978; Shanks et al. 1979). After complete 
blockade, the twitch response starts to recover (99% block) at a 
plasma level of about 0.21 pg/ml(Somogyi et al. 1976; Agoston et al. 
1977b). Pancuronium crosses the placenta (Booth et al. 1977). An 
estimated 2-3% of the injected pancuronium reaches the fetus m 
this way (Duvaldestin et al. 1978°), causing a distribution ratio 
of cord vein to maternal blood of 0.22. Fetal uptake of pancuron­
ium is suggested by a cord arterial to cord venous ratio of 0.66. 
In pregnant women, the elimination of pancuronium is slower than in 
non-pregnant women (Duvaldestin et al. 1978'-'). 
The pharmacokinetics of pancuronium and its pharmacodynamics 
are also influenced by the type of anesthetic used (Miller et al. 
1979). These differences are due partly to circulatory changes and 
partly to alteration of the sensitivity of the neuromuscular junc­
tion (Miller et al. 1979). With age there is a decrease in elimin­
ation of pancuronium from the plasma with a resulting increased 
duration of action (MacLeod et al. 1979). 
In our studies, we determined the pharmacodynamics and pharma­
cokinetics of pancuronium and its metabolites in anesthetized man 
(chapters 3 and 4). 
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CHAPTER 3 
POTENCY OF PANCUROMUM AND ITS METABOLITES IN THE ISOLATED ARM 
TECHNIQUE IN HUMAN VOLUNTEERS 
3.1. The isolated arm technique 
From anunal studies it is difficult to predict the potency and 
duration of action of neuromuscular blocking agents in man. Es-
pecially for the duration of action, a species difference clearly 
exists. This difference is not only dependent on the species used, 
but also on the relaxant studied. Therefore, there is the need for 
an in vivo human preparation to determine the potency and duration 
of action of relaxants before they are used clinically in patients. 
With the normally-used techniques, total body paralysis will occur 
and the volunteers must thus be artificially ventilated. Aside 
from technical problems and risk to the volunteers, this induces 
psychological strain and possible hypoventilation with their re-
spective influence on the blockade. To solve this problem, intra-
venous administration of a small amount of relaxant (diluted in a 
physiological saline solution) into the veins of an occluded arm 
has been described (Torda et al. 1966). This technique has been 
further developed for the diagnosis of myasthenia gravis (Foldes 
1968; Foldes et al. 1968). Use of the method for the study of non-
depolarizing muscle relaxants was initiated (Feldman et al. 1970), 
and is at present accepted for the determination of relative poten-
cy and relative duration of action of such drugs (Bencini et al. 
1980) . 
An indwelling catheter is inserted in a vein on the dorsal 
side of the hand. Then an inflatable tourniquet is placed around 
the upper arm and inflated at a pressure above systolic blood 
pressure, after elevation of the arm for a few minutes to drain the 
blood. A small airount of the relaxant to be studied, diluted in 30 
to 40 ml physiological saline, is administered through this cathe-
ter over a period of 2 minutes. The decrease in the evoked twitch 
response of the adductor pollicis muscle on supramaximal stimula-
tion of the ulnar nerve is recorded. Five minutes after the injec-
tion, the tourniquet is deflated. It has been demonstrated that 
ischemia of 5 minutes' duration does not influence the results and 
that 5 minutes is also sufficient to guarantee diffusion of the re-
laxants from the vessels to the receptors (Agoston, personal comm-
unication) . Since the amount of relaxant administered is small, 
there is no generalized paralysis after deflation of the cuff. 
The effect is measured by quantitation of the adduction force 
of the thumb by a force-displacement transducer. This adduction is 
evoked by supramaximal stimulation of the ulnar nerve near the 
wrist at a rate of 0.1 Hz and 0.2 msec duration. If the volunteer 
so wishes, an ulnar nerve block near the elbow can be applied to 
avoid the experience of pain from the stimulation. 
By studying a great number of volunteers with different doses, 
it is possible to construct a dose response curve with this tech-
nique. When a comparison is made with an already known relaxant, 
an estimate of the potency can be made. If the dose response curves 
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of the drugs to be compared are parallel, the study of one point 
from the dose response curve is sufficient to determine the relative 
potencies. 
Although the duration of action depends on the way the drug is 
administered, i.e. in the isolated arm, as an intravenous bolus, or 
by continuous infusion (Agoston et al. 1979), by comparison an esti­
mate of the duration of action can also be made with this technique. 
In the following section we used this technique to study the separ­
ate effects of pancuronium and its metabolites m man. 
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Summarij 
Of the pancuronium metabolites, only the 3,17-diOH derivative 
has so far been used clinically (Feldman et al. 1970; Norman et al. 
1971). Therefore, the potency of the other derivatives remained to 
be determined in man. From in vitro studies in the rat hemidiaplragm 
preparation and in vivo studies in the rat tibialis muscle prepara­
tion, it is known that pancuronium is about twice as potent as 3-0H-
pancuronium and 40 to 50 times as potent as 17-OH- and 3,17-diOH-
pancuronium (Booij, unpublished observations). In order to have 
some indication of the potency and duration of action, pancuronium 
and its metabolites were compared in the isolated arm preparation in 
awake non-anesthetized man. The dosages used were based on observa­
tions in the rat and on the known potency of pancuronium. 
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Methods 
The isolated arra technique of Feldman and Tyrell (1970) was 
used in four of the authors (LB, RM, JC and SA) to determine the 
relative magnitude and duration of neuromuscular blockade induced 
by pancuronium or its metabolites. The ulnar nerve was stimulated 
near the wrist through thin-wall needle electrodes by a Grass S48 
stimulator. Single supramaximal stimuli were administered at 0.1 Hz 
and a duration of 0.2 msec. Force of thumb adduction was measured 
with a Statham force displacement transducer and recorded on a poly-
graph. By means of two surface electrodes on the hypothenar region, 
and an indifferent surface electrode on the palmar side of the fore-
arm, the evoked compound electromyography (EMG) was also recorded 
on the polygraph (Lee et al., 1977). 
All studies were performed with the subject in the supine posi-
tion. An indwelling needle was inserted into a vein on the forearm, 
and a pneumatic tourniquet placed around the upper arm. A dose of 
relaxant which produced between 80 and 99% depression of twitch ten-
sion was selected and diluted in physiological saline solution to 
40 ml. When twitch tension and EMG were constant, the tourniquet 
was inflated to 200 mmHg, and the drugs were injected into the fore-
arm over two minutes. The tourniquet was kept inflated for five 
minutes to allow retrograde spread of the drug into the capillary 
bed, and was then released. Percent depression to twitch tension, 
time from the end of relaxant administration until 50% recovery of 
the depressed twitch tension (duration), and time from 25 to 75% 
recovery of twitch tension (slope) were calculated from both the 
mechanical and the EMG responses. All volunteers received each 
compound at an interval of one week. Comparison between the com-
pounds was done by analysis of variance. 
Results 
Since there was quite a difference in height and weight of the 
subjects, it was decided that the doses administered be expressed 
in mg/m2. 
The body surface areas and the doses of relaxants administered 
are listed in table 1. 
Table 1. Dose of drugs used in mg/m2 B.S.A. 
Subject *B.S.A. Pane. (mg/m2) 
3-OH 
(mg/m2) 
17-OH 
(mg/m2) 
3,17-OH 
(mg/m2) 
LB 
RM 
JC 
SA 
1.99 
1 .83 
2 . 0 5 
1 .87 
0 . 3 5 
0 . 1 6 
0 . 1 5 
0 . 1 1 
0 . 3 5 
0 . 5 1 
0 . 7 3 
0 . 2 7 
1 0 . 0 5 
3 . 2 8 
9 . 7 6 
3 . 2 1 * * 
7 . 5 4 
1 0 . 9 3 
5 . 8 5 
4 . 2 8 
Mean 1.94 0.19 0.47 7.71 8.11 
* B.S.A. = body surface area in m2. 
**Not included in calculation because of a block of leas than 50% of control 
twitch tension. 
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The mean depressions of mechanical twitch from pancuronium, 
3-0H-, 17-0H-, and 3,17-diOH-pancuronium were 80 + 9 (S.E.), 96 + 2, 
9 0 + 1 , and Θ7 + 8%, respectively. 
EMG was depressed 8 3 + 2 , 8 6 + 4 , 8 4 + 4 , and 76 + 13%, res­
pectively. These neuromuscular blockades were statistically not 
significantly different from each other (p>Q.05). From the mean 
doses listed in table 1, we calculated pancuronium to be 2.4 times 
(0.47/0.19) more potent than 3-OH-pancuronium, 40 times (7.71/0.19) 
more potent than 17-OH-pancuronium, and 42 times (8.11/0.19) more 
potent than 3,17-diOH-pancuronium. 
Although the duration of neuromuscular blockade tended to be 
shorter with 17-OH-pancuronium, no statistically significant diff­
erence existed between the four drugs (p>0.05) (fig. 1). 
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Figure 1. Duration of neuromuscular block­
ade by pancuronium and i t s 3-OH-, 17-0H-, 
and 3,1 7-diOH-nietabolites. 
The slopes of recovery were also not s t a t i s t i c a l l y di f ferent 
(p>0.05) among the four drugs (fig. 2) . 
0 JA 
m, 
3 OH 17 OH 3 17 OH 
Figure 2. Slopes of recovery of pancuronium 
and its 3-OH-, 17-OH, and 3,17-diOH-metabolites. 
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Discussion 
Since 17-0Н-рапсигопішп and 3,17-diOH-pancuronium only have 
about 1/40 the potency of pancuronium, they are not of clinical sig­
nificance. However, 3-OH-pancuronium is approximately half as po­
tent as pancuronium, and could therefore contribute to the neuro­
muscular blockade of pancuronium. Using semiquantitative techniques 
(thin-layer chromatography), Agoston et al. (1973а'Ь) and Buzello 
(1975) have estimated that 20 to 30% of pancuronium is metabolized 
to 3-OH-pancuronium. When enzyme induction occurs, the extent to 
which pancuronium is metabolized could be even greater. An analyti­
cal technique which can accurately measure concentrations of pancur­
onium and its metabolites in body fluids is required to provide 
better information as to how much 3-OH-pancuronium contributes to 
the neuromuscular blockade of pancuronium. 
As observed in previous muscle relaxant studies (Katz, 1971), 
and also in the present study, much variability in the dose of re­
laxant required for 80-99% depression of twitch tension occurred 
from sub3ect to subject (table 1). However, the manner in which 
the variability occurred could not clearly be explained. A subject 
who was particularly sensitive to pancuronium may be comparatively 
insensitive to one of the metabolites, and vice versa. For example, 
subject LB required twice as much 3-OH-pancuronium as subject JC for 
an 80-99% depression of twitch tension. Yet subject JC required 
twice as much 3-OH-pancuronium as subject LB (table 1). We are pre­
sently unable to explain this type of variability. 
The potency ratios between pancuronium and its metabolites 
stated above only represent one point on a dose response curve. We 
believe that establishing potency ratios based on one dose was 
appropriate because the magnitudes of block were similar (no statis­
tically significant difference) among the four drugs studied. If 
the dose response curves deviated from parallelism, then the potency 
ratios between pancuronium and its metabolites may be different at 
different points on the dose response curve. We were unable to det­
ermine complete dose response curves with this method. 
The durations of neuromuscular blockade were all similar. So 
even if a clinically significant amount of 3-OH-pancuroniun were 
formed in a patient receiving pancuronium, the duration of blockade 
should not be significantly prolonged. If they potentiate each 
other, the extent of metabolism may account for part of the varia­
bility in magnitude and duration of neuromuscular blockade from pan­
curonium. 
Of the metabolites, only 17-OH-pancuronium has previously been 
studied in man. Using the isolated arm technique, Feldman and 
Tyrell (1970) found a slope of recovery of 8.4 + 0.8 (S.E.) minutes 
for 17-OH-pancuronium, which is not much different from the 9.5 + 
1.0 minutes observed in our study. 
In summary, we conclude that the duratiors of neuromuscular 
blockade by pancuronium and its metabolites in the isolated arm 
preparation are very similar, and that only the 3-OH-pancuronium 
derivative is potent enough to be of clinical significance. 
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CHAPTER 4 
PHARMACODYNAMICS AND PHARMACOKINETICS OF PANCURONIUM AND ITS 
METABOLITES IN ANESTHETIZED MAN 
4.1. The cumulative dose response curve technique 
Dose response curves are usually constructed by single dose 
administrations followed by linear regression analysis of the total 
number of doses and responses. This requires that a large number 
of patients be studied. When the response can be clearly recorded 
and is also dose-dependent, the cumulative dose response technique 
can be used. Dose response curves are then constructed by incre-
mental administration of cumulating small amounts of the drug. In 
the case of the nondepolarizing neuromuscular blocking agents, each 
incremental dose is administered when 3 subsequent twitches have 
the same height (Donlon et al. 1974). With short-acting compounds, 
the twitch depression may already be recovering before the next dose 
is effective. When longer-lasting drugs are studied, this problem 
does not occur. Since pancuronium and its metabolites are long-act-
ing drugs, we used this technique in our studies. The validity of 
the method has previously been demonstrated (Bavarese et al. 1974), 
and has since been reported more extensively (Donlon et al. 1980). We 
confirmed this validity on several occasions during studies we per-
formed (Booi], Krieg et al., unpublished observations). 
The compound studied must always be injected at a constant 
speed in a fast-running intravenous drip. Stable conditions for 
depth of anesthesia, temperature, and acid-base balance should exist 
during the whole procedure. With this method, no information can 
be obtained on the duration of action and the recovery speed of the 
drug. Such data remain to be obtained from single bolus administra-
tions . 
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ABSTRACT 
Miller, Ronald O., Sandor Agoston, L. H. D. J. 
Bool), Ursula W. Kersten, J. F. Crul and Jay 
Ham: The comparative potency and pharmaco­
kinetics of pancuronium and its metabolites in 
anesthetized man J Pharmacol Exp Ther 
207: 5 3 9 - 5 4 3 , 1978 
To determine the potency of pancuronium and 
its metabolites, 3-OH-, 1 7-OH- and 3,17-OH-
pancuromum, cumulative dose-response curves 
were determined in five anesthetized patients 
with each drug Pancuronium (ED50 = 0 041 
mg/kg) was 2 times more potent lhan 3-OH-
pancuromum (ED50 = 0 082 mg/kg), 50 times 
more potent than 17-OH-pancuronium (ED50 
= 2 0 mg/kg) and 54 times more potent than 
3,17-OH-pancuronium (ED50 = 2 15 mg/kg) 
In 21 other patients, one equipotent dose of 
In cats and man, pancuronium is metabolued 
by deacetylation to 3-hydroxy (З-ОН-рапсигоп-
lum), 17-hydroxy (17-OH-pancuronium) and 
3,17-hydroxy (3,17-OH-pancuronium) bisquater-
nary derivatives (Agoston et al, 1973a,b, Buz-
ello, 1975, Somogyi et al, 1977) As much as 25% 
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either pancuronium or one of its metabolites 
was given as an ι ν bolus Onset time and 
duration of neuromuscular blockade from 3-OH-
and 3,17-OH-pancuronium did not differ signifi­
cantly from that of pancuronium, 1 7-OH-pan-
curomum had a shorter duration of action than 
did pancuronium Although pancuronium 
tended to have a slightly longer elimination half-
life, the pharmacokinetics of the four drugs did-
not differ significantly The elimination half-lifes 
were 110, 68, 73 and 71 mm for pancuronium 
and its 3-OH, 17-OH and 3,17-OH derivatives, 
respectively We conclude that although pan­
curonium is more potent than its 3-OH, 1 7-OH 
and 3,1 7-OH metabolites, the pharmacokinetics 
of these three metabolites do not differ from 
each other and from that of pancuronium 
of an injected dose of pancuronium appears as 
3-OH-pancuronium in the urine and bile of man 
(Agoston et al 1973b, Buzello, 1975, Somogyi et 
al, 1977), however, less than Ъ% of an injected 
dose of pancuronium appears in the urine of 
man as 17-OH- or 3,17-OH-pancuromum (Buz­
ello, 1975; Somogyi et al., 1977) Although 
17-OH-pancuronium has been evaluated clini­
cally (Feldman and Tyrrell, 1970, Norman and 
Kalz, 1971), the potency and pharmacokinetics 
of all three metaboliteb relative to pancuronium 
have not been determined We analyzed the 
pharmacokinetics and compared the magnitude 
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and duration of neuromuscular blockade from 
these metabolites with pancuronium in anesthe­
tized man. 
Methods 
Forty-one patients, 48 ± 5 (S D ) years of age and 
66 ± 3 kg in weight with no hepatic or renal abnor­
malities were studied They had no cardiovascular 
abnormalities with the exception of six patients who 
had systolic hypertension, however, none had a sys­
tolic blood pressure greater than 150 mm Hg No other 
drugs known to interact with neuromuscular blocking 
drugs were being taken by these patients Approxi­
mately 1 hr before anesthesia, they received atropine, 
0 25 mg, dropen dol, 5 mg, and pmtramide, 11 25 mg 
ι m , after which anesthesia was induced with thiopen­
tal, 1 5 to 2 0 mg/kg, γ-hydroxybutync acid, 60 mg/kg, 
and fentanyl, I 5 μg/kg ι ν By controlled ventilation 
PaCOs was maintained between 31 and 40 mm Hg A 
Grass S-44 stimulator was used to administer supra­
maximal square-wave bipolar pulses of 0 2 msec du­
ration to the ulnar nerve at the wnst through thin wall 
needle electrodes at 0 1 Hz The resultant force of 
thumb adduction was quantità ted with a force-dis-
placement transducer and recorded on a polygraph 
(Miller et al, 1977) In addition, by means of two 
surface electrodes on the hypothenar region and an 
indifferent surface electrode on the palmar side of the 
forearm, the electromyograph (EMG) was recorded on 
a polygraph using instrumentation described by Lee 
etat (1977) 
The first section of the study was designed to de-
termine comparative potency between pancuronium 
and its metabolites In the first 20 patients, cumulative 
dose-response curves as described by Uonlon et al 
(1974) were determined for pancuronium and its bis-
quatemary den vati ves No difference was found in 
dose-response curves determined by the cumulative 
method vs the single bolus method (Savárese et al 
1974) Briefly, the patients received a bolus injection 
of pancuronium, 0 025 mg/kg, 3-OH, 0 04 mg/kg, 
17 OH, 0 θ mg/kg or J,17-OH, 0 8 mg/kg ι ν followed 
by incremental doses Before the next incremental 
dose was given, the twitch response to the previous 
dose was allowed lo stabilize as judged by a recording 
of three consecutive twitches of equal tension Five 
patients were studied with each drug while only one 
relaxant was studied in each patient The total amount 
of drug given for each response was calculated and 
plotted on a log dose response graph from which linear 
regression was analyzed From these curves, the ED50 
(dose of relaxant which causes a 50% decrease in twitch 
tension) doses were determined, doses causing either 
no response or a 100% depression of twitch tension 
were not included in the calculation 
To determine the onset time and duration of neu­
romuscular blockade and pharmacokinetics of pancu­
ronium and its metabolites, either pancuronium, 0 04 
mg/kg, 3-OH pancuronium, 0 1 mg/kg, 17-OH pancu­
ronium, 2 mg/kg, or 3,17-OH-pancuronium, 2 mg/kg, 
was administered as an ι ν bolus in the remaining 21 
patients These doses are approximately equipotent as 
determined from the dose-response curves described 
above From mechanical and electromyographic 
twitch recordings, we calculated onset time defined as 
that time from relaxant administration untd peak de­
pression of the twitch, magnitude and duration of 
neuromuscular blockade Duration was defined as that 
time from relaxant administration until recovery of 
50% of the depressed twitch For example, if an 80% 
depression of twitch tension occurred, duration would 
be that time from relaxant administration until recov­
ery to 40% depression of twitch tension (40%/80% -
50%) Slope of recovery was determined as time from 
25 to 75% recovery from the depressed twitch tension 
Venous blood samples were drawn from an indwell­
ing cannula 2, 5, 7, 10, 15, 20, 30, 45, 60, 90, 120, 150 
and 180 mm after the bolus intravenous relaxant ad­
ministration Pancuronium, 3-OH-pancuronium, 
17-OH-pancuronium, or 3,17-OH-pancuronium con­
centrations in plasma were determined fluonmetn-
cally using the method described by Kersten et al 
(1973) of which the lower limit of sensitivity is 0 02 
yg/ml This method does not distinguish between un­
changed pancuronium and its deacetylated metabo­
lites resulting in reported pancuronium concentrations 
being actually a combination of the concentration of 
pancuronium and its metabolites The extent to which 
the reported pancuronium concentration is metabolite 
and not pancuronium would depend on the rate of 
metabolism which is not known The values obtained 
were analyzed by computer using weighted nonlinear 
least squares regression analysis according to a two-
compartment open model (Van Rossum, 1971) The 
data for each subject were fitted to a function of the 
equation С = Ae "' +• Be ^ where С representa the 
plasma relaxant concentration, A and В are h\brid 
intercept terms having units of concentration, and the 
exponents a and β are hybrid rate constants having 
units of reciprocal time From these functions appar­
ent elimination half-life (íi/¿^), volume of central com-
partment ( V\), total volume of distribution at steady 
state ( Vdv.) and total plasma clearance were calculated 
(Van Rossum, 1971, Greenblatt and Koch Weser, 
1975) These results and data obtained from the re-
cordings of mechanical and electromyographic twitch 
were analyzed further by analysis of variance and 
unpaired Student's t test (Goldstein, 1964) 
Results 
In the first phase of the study, the cumulative 
dose method was used to obtain dose-response 
curves The ED50 values for pancuronium, 
3-OH-, 17-OH- and ЗД7-ОН-рапсигопіит were 
0 041, 0 082, 2 0 and 2 15 mg/kg, respectively 
(fig 1) Thus, pancuronium is two times more 
potent than 3-OH-pancuronium (0.082/0 041 = 
2), 50 times more potent than 17-OH-pancuron-
lum (2 0/0 041 = 50) and 53 7 times more potent 
2 7 . 
than 3,17-OH-pancuronium (2.15/0.041 = 53.7). 
With the EMG as the measure, the ED50 values 
were the same as with the mechanical twitch 
except for 17-OH-pancuronium which was 1.57 
mg/kg. 
In the second phase of the study, onset time 
and duration of neuromuscular blockade and 
pharmacokinetics of pancuronium and its deace-
tylated metabolites were determined from the 
i.v. bolus administration of equipotent doses of 
these drugs. The magnitude of maximal depres­
sion of the mechanical twitch from pancuron­
ium, 0.04 mg/kg, 3-OH-pancuronium, 0.1 mg/kg, 
17-OH-pancuronium, 2.0 mg/kg and 3,17-OH-
pancuronium, 2.0 mg/kg, all given as an i.v. 
bolus, were 70 ± 11 (S.E.), 79 ± 7, 56 ± 5 and 4S 
± 5.5%, respectively. With the EMG a 61 ± 11, 
77 ± 4, 52 ± 10 and 49 ± 6% depression occurred 
respectively. No significant difference existed 
between the magnitude of twitch depression 
from these doses of pancuronium and its three 
metabolites. Also, depressions of the mechanical 
twitch were not significantly different from those 
depressions of the EMG. 
Although pancuronium tended to have longer 
onset time than any of its metabolites, these 
differences were not significant (fig. 2). Although 
17-OH-pancuronium, had a significantly shorter 
duration of neuromuscular blockade (P < .05), 
the slopes of recovery of the four drugs were not 
significantly different (fig. 2). There were no 
significant differences between the results ob-
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2 8 . 
tamed from the force displacement transducer 
and the EMO. 
We were unable to demonstrate any signifi-
cant difference in the pharmacokinetics of pan-
curonium and its three metabolites (fig. 3). Al-
though the elimination half-life tended to be 
longer and clearance less with pancuronium, the 
differences were not significant (table 1) 
Discussion 
The 3-OH derivative is half as potent as pan-
curonium (fig. 1). Using semiquantitative tech-
25 50 75 100 125 150 175 
time (mm) 
Fig. 3. Correlation between lime and plasma concen-
tration of pancuronium and its 3-OH, 17-OH or 3.17-
OH derivatives The symbols and bracket represent 
mean ± S E The lines were computed from pharma-
cokinetic data described m the text 
niques (thin-layer chromatography), Agoston et 
al. (1973a,b) and Buzello (1975) identified as 
much as 25% of an injected dose of pancuronium 
as the 3-OH derivative in the urine and bile. The 
17-OH and 3,17-OH derivatives are approxi-
mately 50 times less potent than pancuronium 
(fig. 1) and appear in the urine and bile in an 
amount less than 5% of an injected dose of 
pancuronium (Agoston et al., 1973b, Buzello, 
1975; Somogyi et al, 1977) Consequently, only 
the 3-OH derivative appears in sufficient 
amounts and is potent enough to contribute 
significantly to the neuromuscular blockade of 
pancuronium. 
The results of this study are similar to those 
of studies performed previously which examined 
the pharmacokinetics of pancuronium. We 
found a mean apparent elimination half-life of 
110 min from a dose of 0.04 mg/kg (table 1), 
while McLeod et al. (1976) found a half-life of 
96 mm from a dose of about 0.057 mg/kg of 
pancuronium and Agoston et al. (1973b) found 
the elimination half-life to range from 108 to 147 
mm from a dose of 0.06 mg/kg Somogyi et al. 
(1976) found the elimination half-life to range 
from 89 to 161 mm (mean 132 min) from a dose 
of 6 mg. Somogyi et al. (1976) also found the 
Vdv, to be 261 mg/kg while we found a value of 
241 mg/kg. McLeod et al. (1976) also found the 
V'I and clearance of pancuronium to be 79 ml/kg, 
and approximately 1.1 ml/kg/min, respectively, 
while we found these values to be 72 and 1.76 
ml/kg/min, respectively (table 1). 
Although our data seem to fit the two-com-
partment open model, we cannot exclude the 
possiblity that in other circumstances, other 
models may be more appropriate. For example, 
if sampling had been continued for longer than 
180 mm, perhaps an even slower elimination 
phase might have been observed as with rf-tub-
ocurarme (Gibaldi et al., 1972, Miller et al., 
1977). However, .Somogyi et al. (1976, 1977) 
found that the use of a tn-exponential equation 
did not improve significantly on the fit obtained 
by a bi-exponential equation when sampling was 
continued for 400 min. 
TABLE 1 
Pharmacokinetics of pancuronium and its metabolites (mean + S.E.) 
Drug 
Pancuronium 
3-OH 
17-OH 
3.17-OH 
Dose 
mg/kg 
0 0 4 
0 10 
2 0 
2 0 
110 ± 20 
68 ± 7 
73 ± 6 
71 ± 8 
V, 
ml/kg 
72 ± 10 
66 ± 4 
57 ± 15 
87 r 12 
Vd,, 
ml/kg 
241 ± 27 
205 ± 37 
203 ± 8 
251 ± 35 
Total Plasma 
Clearance 
mllkg/mm 
1 76 ± 0.3 
2.58 ± 0.7 
2.27 ± 0 2 
2 87 + 0 6 
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The precise extent to which these metabolites 
contribute to the neuromuscular blockade of 
pancuronium depends on the amount and rate 
of metabolism although the abo\ e figures prob 
ably underestimate the extent to whit h pancu 
romum is metabolized Although up to 25^ of an 
injected dose of pancuronium has been identified 
as the 3 OH derivative in bile and urine only 40 
to 60S of the total dose of pancuronium was 
recovered (Agoston et al 1971b Вшеііо 1975 
Somogyi et al, 1977) Τ he remaining 40 to 60% 
of pancuronium which was not recovered may 
have been significantly metabolized and the rate 
at which pancuronium is metabolized is not 
known The above figures refer to urine and bile 
analyzed after 12 (Buzello, 1975) 24 (Somogyi 
et al 1977) and 30 hr (Agoston et al 197 )b) 
In order to pro\ ide more precise information 
about the amount and rate of pancuronium me 
tabolism, a better method of analysis is required 
The fluonmetnc method measures the concen 
tration of the total bisquaterndry ammonium 
compound and does not distinguish between un 
changed pancuronium and its deacetylated me 
tabohtes which may lead to inaccurate conclu 
sions in some studies For example McLeod 
(1976) found that renal failure markedly pro 
longed the elimination half life of pancuronium 
and assumed that the delayed elimination from 
plasma represents accumulation of pancuron 
mm However it may in fact represent accu 
mulation of relatively inactive metabolites In 
our study it is possible that the pancuronium 
and 1 OH pancuronium plasma decay curves 
represent some contribution from 17 OH and 
3,17 OH pancuronium If the metabolic conver 
Sion of pancuronium to its metabolites is sequen 
tial, an underestimation of the rate of decay of 
pancuronium from plasma may occur ( ι e the 
elimination half life may be shorter) This may 
account for the slightly longer (although statis 
tically insignificant) elimination half life of pan 
curomum Because the semiquantitative studies 
of Agoston et al (1973b) Buzello (1975) and 
Somogyi et al (1977) suggest limited metabo 
lism of pancuronium and because of the possible 
shorter half lives of the metabolites we think 
this is unlikely However, definitive proof awaits 
a more precise method for measuring pancuron 
mm concentrations 
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CHAPTER 5 
INTERACTION BETWEEN PANCURONIUM AND EACH OF ITS DEACYLATED 
METABOLITES IN IN VIVO AND IN VITRO RAT PREPARATIONS 
Leo H.D.J. Booij, M.D., Ronald D. Miller, M.D., Laura Roderick, 
Francien van der Pol, Jan F. Crul, M.D., Ph.D. 
Submitted to Anesthesiology 
Abs tract 
We studied the interaction of pancuronium and its metabolites 
in vivo and in vitro rat muscle preparations. In vivo, the effect 
of the metabolites was additive to the effect of pancuronium. In 
vitro, however, a slight antagonism was observed. A cardiovascular 
explanation was proposed. It is concluded that the interaction of 
pancuronium and its metabolites is not important to the activity of 
pancuronium. Prolonged pancuronium blockade and problems with re­
versibility can thus not be explained from such an interaction. 
Introduotion 
Prolonged neuromuscular blockade from pancuronium, and problems 
in reversing the blockade may be the result of several factors. 
Different pharmacokinetics, as compared to normal, in patients with 
renal failure or hepatic diseases have been demonstrated (McLeod 
et al. 1976; Somogyi et al. 1977а'Ь). Hypothermia produces a aifrer-
ent pharmacokinetic behavior (Miller et al. (1У78а), and acid-base 
balance disturbances mainly influence the pharmacokinetics as well 
(Crul-Sluijter et al. 1974; Miller et al. 1976). Pancuronium is par­
tially metabolized by deacetylation (Agoston et al. 1973a'^; Buzello 
1975). The resulting hydroxy derivatives possess neuromuscular 
blocking activity (Miller et al. 1978':') . Nevertheless, theoretical­
ly only the 3-OH metabolite may contribute to the pancuronium block­
ade because of the amount produced and its potency. The metabolites 
do not differ from pancuronium pharmacokinetically (Miller et al. 
19781:,) . For reversal of equal degrees of blockade, the 17-OH and 
3,17-OH derivatives need significantly more neostigmine, but all can 
be reversed completely (Booij et al. 1979). Therefore, prolonged 
duration of action and problems in reversing pancuronium blockades 
are not likely to be the result of the potency, pharmacokinetics, or 
reversibility of the individual metabolites. A remaining possibili­
ty may be an interaction between pancuronium and its metabolites. 
In this study we determined whether such an interaction exists in 
both in vitro and in vivo rat preparations. 
Methods 
A. In vitro rat hemidiaphragm preparation 
Rat hemidiaphragms suspended in a Krebs solution at a constant 
temperature of 370C, bubbled with a carbon dioxide 5% and oxygen 95% 
mixture, were supramaximally stimulated. The st- mli were delivered 
by a Grass S44 nerve stimulator at a rate of 0.' > Hz and 0.2 msec 
duration. When twitch height remained constar a dose of pancuron-
31. 
iura or one of its metabolites was added to tbe bathing fluid, resulting 
in a depression of twitch height. Incremental doses of the same com­
pound were added and the resulting twitch depression recorded. Linear 
regression analysis of the data resulted in cumulative dose response 
curves for pancuronium and each of its metabolites. In the next 
group of hemidiaphragms, pancuronium or one of the metabolites was 
added to the bathing fluid in a 10% blocking dose. Incremental a-
mounts of pancuronium were again administered, and linear regres­
sion analysis of the data performed. The dose response curves 
pancuronium were compared by analysis of covariance. ECso's (con­
centration resulting in 50% depression of twitch tension) were 
calculated from the regression line. 
B. In vivo rat muscle preparation 
Rats were anesthetized with pentobarbital 40 mg/kg intrapen-
toneally. Via a tracheostomy, ventilation was controlled by a Braun 
air pump. The left jugular vein was cannulated for drug administra­
tion. Arterial blood pressure was continuously monitored through a 
cannula in the left carotid artery. The tibialis muscle tendon was 
freed and connected to a force displacement transducer with the rest­
ing tension adjusted to 20 gm. A Grass S44 stimulator delivered 
supramaximal stimuli to the sciatic nerve at a rate of 0.1 Hz and 
0.2 msec duration. The resulting twitch tension was recorded on a 
polygraph, together with the arterial blood pressure and heart rate. 
Rectal and muscle temperature were maintained at between 37 and 380C. 
When twitch tension was constant for 10 minutes, a constant 10 to 
15% twitch depression was obtained by continuous infusion of pancur­
onium or one of its metabolites. Then incremental doses of pancur­
onium were administered to construct a cumulative dose response 
curve. Each consecutive dose was administered when 3 succeeding 
twitches were of the same height. Linear regression analysis of the 
data resulted in dose response curves. Analysis of covariance was 
performed to compare the regression lines with each other. EDSQ'S 
(dose resulting in 50% depression of twitch height) were calculated 
from the regression lines. 
Results 
A. In vitro rat hemidiaphragm 
Cumulative dose response curves for pancuronium and each of its 
deacylated metabolites (fig. 1) did not deviate from parallelism 
(p>0.50). Except for 17-0H- and 3,17-diOH-pancuronium (p>0.05), 
they were significantly different from each other (p<0.01). Pancur­
onium was 2.36 times more potent than 3-OH-pancuronium, 50.52 times 
more potent than 17-0H-pancuronium, and 45.24 times more potent than 
3,17-diOH-pancuronium. Their ЕВзд'з were 1.878 yg/ml, 4.435 pg/ml, 
94.876 pg/ml, and 84.954 pg/ml, respectively. In 8 hemidiaphragms, 
pancuronium 1.27 pg/ml-1 (the blocking dose) was added to the bathing 
fluid, resulting in 6.5 ± 3.9% depression of the twitch height, and 
a cumulative dose response curve for pancuronium was again determined 
(fig. 2). 
In another 8 diaphragms, 3-OH-pancuronium 2.75 vig/ml-1 was added 
to the bathing fluid, resulting in a 3.3 ± 3.3% depression of twitch 
height, and a cumulative dose response curve for pancuronium was 
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determined (fig. 2). The same was done in 12 hemidiaphramgs with 
66.1 vg/ml 3,IT-diOH-pancuronium, resulting in 4.2 ± 4.4% depression 
(fig. 2). Although they were shifted to the left, the obtained dose 
response curves did not deviate from parallelism (p>0.50), and were 
not different from each other (p>0.50) (fig. 2). All these loading 
doses were equipotent to 1.27 pg/ml-! pancuronium. When a correction 
was made for the additional dose, the shift of the dose response 
curves disappeared completely and the curves were not different from 
the original pancuronium dose response curve (p>0.50). ЕОзо'з were 
calculated from the dose response curves and corrected for the load­
ing dose (table 1). There was no difference between these EDßo's; 
if anything, there was antagonism of pancuronium by its metabolites 
in vitro. 
Table 1. EDso's for pancuronium with and without a loading dose 
of pancuronium, 3-OH-pancuronium, 17-OH-pancuronium, or 3,17-diOH-
pancuronium equipotent to 1.27 pg/ml pancuronium. 
ED50 ED50 corrected 
pancuronium 
pancuronium + pancuronium 
pancuronium + 3-OH-pancuronium 
pancuronium + 17-OH-pancuronium 
pancuronium + 3,17-diOH-pancuronium 
1.88 
0 . 8 3 
0 . 7 9 
1.00 
1 .01 
1 .88 
2 . 1 0 
2 . 0 6 
2 . 2 7 
2 . 2 8 
B. In vivo rat tibialis muscle preparation 
Constant infusions of pancuronium causing a constant 15.2 + 5.2% 
twitch depression, 3-OH-pancuroniuin resulting in 14.5 ± 3.7% twitch 
depression, 17-OH-pancuronium giving a 14.5 ± 10.3% twitch depression, 
and 3,17-diOH-pancuronium leading to 12.5 ± 5.9% depression were res-
pectively administered in the successive groups of rats. The depres-
sion of twitch height by these continuous infusions were not differ-
ent from each other (p>0.50). Then a cumulative dose response curve 
for pancuronium was made on top of this (fig. 3). The resulting 
curves did not deviate from parallelism (p>0.50). Although there was 
a tendency towards significant difference when 3-OH-pancuronium was 
infused (p<0.10), there was only a difference for 17-OH and 3,17-diOH 
from pancuronium (p<0.01). This means that in vivo there may be an 
antagonistic effect by the metabolites on the activity of pancuronium. 
Ог s eus s г en 
Pancuronium is metabolized in the human body. It is most likely 
that the metabolites are the 3-(JH, 17-OH, and 3,17-diOH derivatives. 
In plasma, urine, and bile, only 3-OH-pancuronium has so far been 
detected in relevant amounts. With improvement of tne detection 
methods, rate and exact amount of metabolism may be determined. That 
all proposed metabolites possess neuromuscular blocking activity 
(Miller et al. 1978b)
 Was confirmed in this study (fig. 1). When 
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Figure 2. In vitro cumulative concentration 
response curves for pancuronium when a small 
amount of a metabolite or pancuronium is added 
to the bathing fluid (o—o: pancuronium; X—X: 
3-OH-pancuronium;·-·: 1 7-0H-pancuronium; ..-LJ: 
3,17-di0H-pancuronium). 
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Figure 3. Cumulative dose response curves for pancuronium m 
vivo on top of a constant 10% blockade by pancuronium or one 
of i t s metabolites in rats (O—0: pancuronium; X—X. 3-0H-pancur-
onium; ·—·: 17-OH-pancuronium; — : 3,17-di0H-pancuronium). 
a d n u n i s t e r e d s i m u l t a n e o u s l y in v i t r o , each of t h e m e t a b o l i t e s and 
pancuronium had an a d d i t i v e e f f e c t . In vivo t h e r e was an antagon­
i z i n g e f f e c t of t h e m e t a b o l i t e s upon pancuronium. This was 
e s p e c i a l l y so wi th 17-OH and 3,17-diOH-pancuronium. These two com­
pounds p o s s e s s more c a r d i o v a s c u l a r e f f e c t s than pancuronium and 3-0H-
pancuronium (Booi j , unpubl i shed o b s e r v a t i o n s ) , and may t h e r e b y i n ­
f l u e n c e t h e a v a i l a b i l i t y of pancuronium a t t h e r e c e p t o r . In p a t i e n t s 
r e c e i v i n g 17-OH or 3,17-diOH-pancuronium, m y d r i a s i s and b r a d y c a r d i a 
were observed i n most cases (Booi j , unpubl i shed o b s e r v a t i o n s ) . Con­
t r a r y t o m i x t u r e s of o t h e r n o n d e p o l a r i z i n g r e l a x a n t s (Wong e t a l . 
1971; Park e t a l . 1974), t h e e f f e c t s of pancuronium and i t s metabol­
i t e s in v i t r o a r e only a d d i t i v e . In vivo t h e r e i s a tendency t o ­
wards antagonism. This means t h a t t h e metabolism of pancuronium i s , 
c o n s i d e r i n g i t s i n t e r a c t i o n , not an i m p o r t a n t f a c t o r in e x p l a i n i n g 
prolonged pancuronium blockade or problems with r e v e r s a l . 
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CHAPTER 6 
REVERSIBILITY OF PANCURONI UM-INDUCED NEUROMUSCULAR BLOCKADE 
6.1. The effect of Cholinesterase inhibiting drugs; A literature 
review 
Nondepolarizing neuromuscular blockades can be reversed by 
cholinesterase-inhibiting drugs (Miller 1976a). In the literature 
many case reports appeared on recurarisation and irreversibility of 
blockades (Baraka 1967; Miller et al. 1976ь). Most cases can be 
explained by inadequate antagonism due to the administration of in­
sufficient amounts of Cholinesterase inhibitors (Lee et al.1977). Prob­
lems with reversibility of pancuronium blockade in other cases are 
due to factors influencing the effect of the anticholinesterasic 
drugs. The mechanisms by which the anticholinesterases exert their 
effect are (Katz 1967): 
1. inhibition of true Cholinesterase, 
2. increase in acetylcholine release, 
3. acetylcholine-like stimulation of motor end-plate receptors, 
4. displacement of curarizing drug from the postjunctional 
receptors, and 
5. repetitive firing in the motor nerve. 
It has not as yet been established which mechanism is the most im­
portant for the anticurarc effect. This may depend partly on the 
anticholinesterase drug administered (Smith et al. 1952; Blaber et 
al. 1959; Blaber 1963a; Blaber et al. 1963ь; Barrow et al. 1966; 
Blaber 1972; Lee et al. 1978; Tiedt et al. 1978; Main 1979). In 
clinical practice, neostigmine and pyridostigmine are most usually 
used. Edrophonium is less popular since some authors feel its dura­
tion of action is too short, and its effect unreliable (Katz 1967; 
Nastuk et al. 1954). This has recently been denied (Lee et al. 1977; 
Sevan 1979; Kopman 1979). 
Neostigmine is about 4 to 5 times as potent as pyridostigmine 
in antagonizing pancuronium blockade (Fogdall et al. 1973; Gyermek 
1975) , while its anticholinesterase activity is 20 times as strong 
(Randall et al. 1955) . Edrophonium is ï as potent as neostigmine 
in antagonizing neuromuscular blockade (Randall 1951) with an anti-
cholinesterase activity that is 1/100 to 1/200 that of neostigmine 
(Bevan 1979; Randall et al. 1955). Pyridostigmine and edrophonium 
are said to result in comparatively less severe muscarinic side 
effects. Pyridostigmine should therefore lead to less severe cardio-
vascular side effects (Gyermek 1975). Also, compared to the other 
compounds, it causes less increase in intestinal motility, and is 
therefore likely to result in less disrupture of intestinal anasto-
moses (Brown et al. 1973) . Other groups found no difference in 
cardiovascular side effects between neostigmine and pyridostigmine 
(Fogdall et al. 1973). Onset time and duration of action of pyrido-
stigmine are longer (5-7 minutes and 40%, respectively) than with 
neostigmine (Miller et al. 1974). 
The amount of Cholinesterase inhibitor necessary for antagonism 
depends on the depth of block and not on the amount of relaxant ad-
ministered (Miller et al. 1972). The activity of neostigmine, and 
probably also of pyridostigmine, is affected by disturbances in the 
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acid-base balance. In the case of respiratory acidosis, neostigmine 
is unable to completely reverse a pancuronium neuromuscular blockade 
(Miller et al. 1978 a), while pancuronium in these circumstances is 
more potent (Crul-Sluijter et al. 1974) . When metabolic alkalosis 
exists, the effectiveness of neostigmine is decreased and its duration 
of action shortened (Miller et al. 1978 a). A decrease in temperature 
does not influence the efficiency of neostigmine, but its onset and 
duration of action are prolonged (Miller et al. 1977 a). In the case 
of hypothermia, however, pancuronium is potentiated by changes in 
pharmacokinetics and increased receptor sensitivity (Miller et al. 
1978b)
<
 Thus, more neostigmine (and probably more pyridostigmine) is 
necessary to reverse a blockade in hypothermia. For this reason, 
recuransation upon warming up a patient is unlikely, as has previous­
ly been found (McKlveen et al. 1973). 
When renal failure exists, the duration of pancuronium blockade 
is prolonged, as well as the effects of neostigmine and pyridostig­
mine (Miller et al. ІЭ??13). This has recently been proven pharmaco-
kinetically (Cronnelly et al. 1979); the elimination half-life time 
is prolonged and the total serum clearance diminished. Hypokalaemia 
increases the amount of neostigmine required to antagonize a pancur­
onium blockade (Miller et al. 1978 е). 
Edrophonium possesses less severe muscarinic side effects and 
its onset of action is much faster. Combination with pyridostigmine 
may be advantageous (Gyermek 1977). 
The muscarinic side effects of the Cholinesterase inhibitors 
are due to accumulation of acetylcholine at the muscarinic receptor 
(Owens et al. 1978) . Atropine can block this receptor and therefore 
decrease these side effects. However, atropine has a shorter dura­
tion of action, possibly resulting in a subsequent period of brady­
cardia when its effect has worn off. Muscarinic receptors are pre­
sent in the presynaptic part of the cardiac sympathetic nerve and 
influence catecholamine release (Sharma et al. 1978). Acetylcholine 
accumulation inhibits noradrenaline release and causes bradycardia 
through this mechanism. Since this noradrenaline is released at the 
ß-adrenergic junction (Lokhandwala 1979), ß-blockers in combination 
with Cholinesterase inhibitors may cause adverse reactions (Heinonen 
et al. 1977). Also, interaction between neostigmine and amitrypti-
line has been described (Glisson et al. 1978). All these adverse 
reactions of the anticholinesterases can be diminished by decreasing 
the dosage. It recently became obvious that this is possible by 
combining neostigmine or pyridostigmine with 4-aminopyridine (Chapter 
6.5 and 6.6). Due to all the afore-mentioned reasons, only one poss-
ibility for failing antagonism of pancuronium remains. Since pancur-
onium is metabolized (Chapter 2), there may for some reason be an ac-
cumulation of the metabolites. These metabolites may not be reversi-
ble by Cholinesterase inhibitors. We have investigated this (Chapter 
6.3.) . 
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6.2 Aminopyridines and neuromuscular transmission; A literature 
review* 
Although 4-aminopyridine (4-AP) was already tested pharmacolo­
gically in the mid-twenties (Dohrn 1925; Dingemanse et al. 1928), 
it took until the late sixties before great interest was payed to 
it (Lemeignan et al. 1967, Sobek et al. 1968). Development of more 
sophisticated electrophysiological techniques and increased atten­
tion to membrane processes were responsible for this. Increased 
intestinal motility and hypertension upon injection of 4-AP were 
demonstrated early (Dohrn 1925) as were the local anesthetic and 
convulsive effects (Dingemanse et al. 1928). These results were 
confirmed m later experiments (rastier 1948; Tastier et al. 1948; 
Abernethy et al. 1958; Fastier et al. 1958а»Ь
; v o n
 Haxthausen 1955). 
It was concluded that the aminopyridines produced sympathicomimetic 
effects (von Haxthousen 1955) both peripherally and centrally. 
Later on it was demonstrated that this sympathicomimetic effect was 
not caused by an adrenergic mechanism but by a cholinergic mechanism 
(Lemeignan 1971) . 
In 196 7 it was found that 4-AP antagonized the neuromuscular 
blocking effects of d-tubocuranne and gallamine. The exact mech­
anism of action remained unknown, although the conclusion from the 
experiments was that it was neither an anticholinesterase effect nor a 
direct effect on postsynaptic acetylcholine receptors or muscles 
(Lemeignan et al. 1967). Sobek demonstrated that the effect was 
mainly caused by a presynaptic effect (Sobek et al. 1968). In­
creased acetylcholine release was thus postulated. As explanation 
for this increased release, blockade of potassium channels result­
ing in prolongation of the action potential was found (Hue et al. 
1973). Such a blockade has been demonstrated for both inward and 
outward potassium currents (Pelhate et al. 1974; Yeh et al. 1976 a). 
Although it was originally stated that 4-AP blocked the potassium 
channels intra-cellularly (Gillespie et al. 1975; Ulbricht et al. 
1976), both intra- and extra-cellular sites of action have now been 
found (Meves et al. 1975; Yeh et al. 1976 ь). Extra-cellularly, 4-AP 
is able to block open potassium channels, whereas intra-cellularly, 
4-AP can block closed channels at depolarization of the membranes 
(Gillespie 1977) . There is no effect on sodium conductance (Schauf 
et al. 1976), but an increased calcium movement is observed (Nichol­
son et al. 1976). This is probably due to the prolonged action po­
tential (Leander et al. 1977). The increased intra-cellular calcium 
then leads to increased quanta! acetylcholine release (Lundh et al. 
1977 a). The increased acetylcholine release by 4-AP mediated by 
calcium has been clearly demonstrated both pharmacologically (Vizi 
et al. 1977; Ules et al. 1978; Lundh 1978; Kim et al. 1980) and 
morphologically (Tokunaga et al. 1979a'1:,) . 4-AP cannot replace cai-
cium ions, which is another proof for calcium mediation (Al-Haboubi 
et al. 1978). It has recently been proposed that 4-AP acts directly 
on calcium channels (Molgo et al. 1979). Such a direct calcium 
effect is also likely to exist in both skeletal and heart muscle 
where 4-AP can increase contractility. It is likely that in these 
tissues 4-AP either causes a release of calcium from binding or 
storage sites, or slows down the binding of calcium intra-cellularly 
(Yanagisawa et al. 1979). Increased calcium in the muscle then 
•Part of a paper submitted to Anesthesiology. 
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leads to increased contractility. That calcium is involved can 
also be concluded from the fact that 4-AP antagonizes dantrolene-
induced muscle relaxation by blocking calcium release from the 
sarcoplasmic reticulum. It can be concluded that 4-AP increases 
the amount of acetylcholine release from the presynaptic membrane 
at the motor nerve terminal. 
Increased transmitter release by 4-AP is not only seen at the 
neuromuscular synapse, but also at other sites. Increased contrac­
tility of the guinea pig ileum due to increased acetylcholine 
release has been shown (Montoki et al. 1978). This cholinergic 
mechanism is also responsible for the initial sinus bradycardia in 
isolated sino atrial node preparations of the dog (Yanagisawa et 
al. 1978). The tachycardia seen with higher amounts of 4-AP is 
thought to be mediated by adrenergic mechanisms. 4-AP is not only 
effective in facilitating the transmission in skeletal muscle, but 
also in smooth muscles with adrenergic and cholinergic terminals 
(Al-Haboubi et al. 1978). Increase in phrenic nerve activity lead­
ing to ventilatory stimulation may be due to central cholinergic 
effects (Folgering et al. 1979; See et al. 1978). Besides this, 
4-AP increases the release of noradrenaline in various organs such 
as the rabbit vas deferens (Johns et al. 1976) and ear artery 
(Glover et al. 1978), the cat spleen (Kirpekar et al. 1977), the 
rat portal vein (Leander et al. 1977) , and the guinea pig pulmonary 
artery (Hara et al. 1980). 4-AP even reverses the respiratory de­
pression caused by fentanyl (Sia et al. 1979). Anesthesia induced 
by ketamine is also reversed by 4-AP (Martmez-Aguirre et al. 1979; 
Agoston et al. 1980). Another effect that has been demonstrated is 
the prolongation of action potentials in rat pituitary cell culture 
and the facilitation of prolactine release (Sand et al. 1980). 
It must therefore be concluded that 4-AP, by blocking potassium 
channels, causes a calcium-mediated increase of transmitter release 
in several synaptic systems both of cholinergic and adrenergic ori­
gin. Thus, 4-AP has many effects, only a few of which will be dis­
cussed here. 
Effects on neuromuscular transmission 
That 4-AP influences neuromuscular transmission was seen in 
1967 as an antagonistic effect on d-tubocuranne and gallamine-
rnduced neuromuscular blockades (Lemeignan et al. 1967). The mech­
anism was neither due to direct muscle effect, postsynaptic acetyl­
choline receptor effect, nor to an anticholmesterasic effect. 
However, many groups demonstrated an increase in quantal acetylcho­
line content (Bowman et al. 1977ь, Harvey et al. 1977a; Vizi et al. 
1977; Moritoki et al. 1978; liles et al. 1978). Such a quantal 
content is only increased when the release is evoked (Lundh 1978); 
there is no increase in spontaneous release. However, increased 
frequency of stimulation, i.e. above 8 Hz, shows fading of the 
response. This means that 4-AP only increases release of acetyl­
choline and not its mobilization from storage sites (Molgo et al. 
1979; Khan et al. 1979). 
4-AP via calcium also exerts a direct muscle effect. The increase 
in intra-cellular calcium increases contraction of the muscle fibers 
(Bowman et al. 1977ь; Bowman et al. 1979; Harvey et al. 1977a). Via 
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this mechanism, 4-AP is able to antagonize dantrolene-induced muscle 
relaxation (Bowman et al. 1977 a). Since increased calcium release 
is thought to be the trigger in the development of malignant hyper­
thermia, it was expected that 4-AP could induce this syndrome in 
susceptible animals. However, experiments in pigs proven to have 
malignant hyperthermia could not show such an action (Hall et al. 
1980) . 
4-AP not only exerts its action when nondepolarizing neuromuscu­
lar blocking agents have impaired neuromuscular transmission, but 
also when impaired transmission is due to other factors. It has been 
shown that Eaton-Lambert syndrome can be efficiently treated with 
4-AP (Lundh et al. 1977 ь; Agoston et al. 1978; Kim et al. 1980 ь). 
After experimental demonstration of the reversibility of botulinum 
toxin paralysis (Lundh et al. 1977 е), some patients have been treated 
successfully (Ball et al. 1979). 
4-AP increases muscle strength in patients with myasthenia gravis 
(Lundh et al. 1979). Aminoglycosides, polymyxin B, tetracyclines, 
lincomycine and clindamycme are known to cause neuromuscular blockade 
and to enhance the effect of nondepolarizing relaxants. Their anta-
gonisability with Cholinesterase inhibitors is questionable. 4-AP 
has proven to be the only reliable and efficient antagonist for these 
compounds (Booi] et al. 1978; Singh et al. 1978; Burkett et al. 1979; 
Lee et al. 1979, 1978; Bruckner et al. 1980; Rutten et al. 1981). We 
studied whether 4-AP antagonized the antibacterial activity of the 
antibiotics as well (Chapter 6.8). 
Although 4-AP has been advocated for clinical use in the antagon­
ism of nondepolarizing neuromuscular blockades (Stoyanov et al. 1976), 
it is only adequate when administered in amounts that cause central 
nervous system effects. Thus, it should not be used for this purpose. 
Since 4-AP enhances acetylcholine release, and Cholinesterase inhibi­
tors decrease the breakdown of acetylcholine, interactions between 
these compounds may exist. We were able to demonstrate these inter­
actions (Chapter 6.5, 6.6, 6.7). Also, 3,4-di-AP acts by blockade of 
potassium channels leading to prolongation of the falling phase of 
the action potential, enhancing acetylcholine release (Kirsch et al. 
1978). It is an even better neuromuscular transmission facilitating 
drug than 4-AP (Durant et al. 1978, 1980; Harvey et al. 1977 ь; Molgo 
et al. 1980). 
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Antagonism of Pancuronium and Its 
Metabolites by Neostigmine in Cats 
Leo H.D.J. Booij, M D / Ronald D. Miller, MD/f Marjorie J. W. Jones,}: and 
Donald R. Stanski, MD§ 
Boou L H D J MILLER R D JONES M J W AND STANSKÎ D R Antagonism of pancuro-
nium and its metabolites by neostigmine m cats Anesth Analg 5Θ 4Θ3-4Θ6 1979 
Antagonism by neostigmine of r euromjscular blockade produced by pancuronium or its 
metabolites was studied in the cat anterior tibialis muscle-peroneal nerve preparation using 
constant infusions of muscle relaxants The EDso of neostigmine (dose which caused a 50% 
antagonism) was 16 11 29 and 26 ^g ''kg for pancuronium 3-hydroxypancuronium 17 
hydroxypancuromum and 3 17 hydroxypancuromum respectively Times of onset of neostig­
mine action were shorter when antagonizing 17-hydroxypancuronium neuromuscular block­
ade Duration of neostigmine action when antagonizing 1 7- or 3 17-hydroxypancuronium 
blockade was shorter than with pancuronium or 3-hydroxypancuronium We conclude that 
more neostigmine is required to antagonize 17 or 3 17-hydroxypancuronium neuromuscular 
blockade than is required to antagonize pancuronium Conversely less neostigmine was 
required to antagonize 3-hydroxypancuronium blockade 
Key Words NEUROMUSCULAR RELAXANTS pancuronium BIOTRANSFORMATION (DRUG) pancuronium 
REVERSAL of a pancuronium neuromuscular blockade is occasionally difficult particularly 
after prolonged administration or in patients with 
renal or hepatic dysfunction l 2 One explanation is 
that delayed plasma clearance of pancuronium may 
result in a neuromuscular blockade too intense to be 
antagonized * Another possibility is that with im­
paired routes of excretion, metabolites of pancuro­
nium may accumulate and cause a neuromuscular 
blockade in addition to that produced by pancuro-
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mum As much as 20 to 30% of an injected dose of 
pancuronium may be metabolized into one of its 
hydroxylated metabolites * In man pancuronium was 
found to be 2 50 and 52 times as potent as its 
metabolites 3-hydroxypancuronium 17 hydroxy 
pancuronium and 3 17 hydroxypancuromum 6 In this 
study we determined the ability of neostigmine to 
antagonize the neuromuscular blockade produced by 
the hydroxylated metabolites of pancuronium 
Methods 
Twenty seven cats were anesthetized with chlora-
lose 250 mg/kg and urethane 60 mg/kg tntrapen-
toneally Ventilation was controlled thereafter via a 
tracheostomy Both external jugular veins were can-
nulated for administration of drugs Arterial blood 
pressure was recorded from a cannula in the carotid 
artery The tibialis anterior muscle tendon was freed 
sectioned near its point of attachment and attached to 
a Grass FT10 force displacement transducer A stim 
ulating shielded platinum bipolar electrode was 
placed on the sciatic nerve after it had been sectioned 
near its point of attachment Supramaximal stimuli 
48. 
were delivered at a rate of 0 15 Hz and 0 2 msec 
duration The resultant twitch contraction was re­
corded on a polygraph Temperature was maintained 
between 36 5 and 37 5 С After an intravenous bolus 
of pancuronium or one of its metabolites, a continu­
ous infusion with the same compound was started at 
a rate adequate to maintain 90% depression of twitch 
tension When depression of twitch tension and rate 
of infusion were constant for at least 20 minutes, a 
bolus of neostigmine, 5, 10, 20, 30, 50, or 70 /ig/kg 
was administered intravenously, while the infusion of 
relaxant continued The TO-jig/kg dose wa$ studied 
only when reversing a 17-hydroxypancuronium neu­
romuscular blockade Fürth e ι details of this constant-
infusion technique have been desenbed previously ' 
The resultant maximal antagonism of twitch depres­
sion was calculated as a percentage of the preexisting 
90% twitch depression We also measured the time 
from the administration of neostigmine to peak effect 
(onset time) and to 50% restoration of the muscle 
relaxant depressed twitch tension (duration of action) 
Subsequent doses of neostigmine were given after the 
twitch had returned to and remained stable at 90% 
depression for at least 1 hour The doses of neostig­
mine were given by random selection 
Linear regression analysis and unpaired f-tests were 
earned out for part of the statistical analyses Dose-
response curves of neostigmine while antagonizing 
pancuronium and its metabolites were compared by 
analysis of covanance and the Sheffe's multiple con­
trast procedure β 
Results 
The doses of neostigmine required for antagonism 
of a pancuronium neuromuscular blockade and for 
antagonism of its metabolites differed significantly (F 
« 24 6 ρ < 0 001) (Fig 1) The ED» (dose of neostig­
mine which caused a 50% antagonism) was 16, 11, 29, 
and 26 μg/kg for pancuronium, 3-hydroxypancuro-
mum, 17-hydroxy pa neuroni urn, and 3,17-hydroxy-
pancuromum, respectively (Fig 1) Analysis of the 
dose-response curves in Fig 1 indicate that (1) More 
neostigmine was required to antagonize a neuromus­
cular blockade from 17-or3,17-hydroxypancuronium 
than was required to antagonize neuromuscular 
blockade produced by 3-hydroxypancuronium or 
pancuronium itself ( ρ < 0 05) (2) Less neostigmine 
was required to antagonize a 3-hydroxypancuronium 
neuromuscular blockade than was required to antag­
onize a pancuronium block ( ρ < 0 05) (3) Neostig­
mine dose-response curves were the same for 17- and 
5 10 20 30 50 Θ0 100 
NEOSTIGMINE <juQ/kg) 
FIG 1 Correlation belween dose of neosligmme and percent 
antagonism of twitch depression induced by pancuronium, Э-
hydroxypancuronium (3 OH-Pc) 17-hydroxypancuronium 
(17 OH-Pc) or Э 17-hydroxypancuronium (3 17 OH-Pc) Unes 
represent analysis of linear regression Symbols are means ± 
SE See Fig 2 lor the number ol studies at each dose With 
neostigmine 70 μg/kg. two studies were performed when an­
tagonizing 17 OH-Pc 
3117-hydroxypancuronium ( ρ > 0 10) (4) Neostig­
mine dose-response curves did not deviate from par­
allelism ( ρ > 0 10) 
The onset times of neostigmine were shortest when 
antagonizing a 17-hydroxypancuronium blockade ( ρ 
< 0 05) (Fig 2) Duration of action of neostigmine 
when antagonizing a 17- or 3,17-hydroxypancuro-
mum neuromuscular blockade was less than when 
pancuronium or 3-hydroxypancuronium were being 
antagonized ( ρ < 0 05) (Fig 2) 
Discussion 
As much as 20 to 30% of an injected dose of 
pancuronium is metabolized pnmanly to 3-hydroxy-
pancuronium and to a lesser extent 17- and 3,17-
hydroxypancuromum 5 Because only 50 to 60% of the 
administered pancuronium usually is recovered in the 
urine and bile of most studies,5 a 1 0 the actual extent 
to which pancuronium is metabolized may, however, 
be more than estimated 3-Hydroxypancuronium is a 
moderately potent neuromuscular blocking agent 
However, even if large amounts of this metabolite 
were to accumulate after pancuronium, no problem 
with antagonism should occur since less neostigmine 
is required to antagonize the neuromuscular blockade 
49. 
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FIG 2 Comparison of onset time (lime from neostigmine admin­
istration to peak effect) and duration of action (time from neo­
stigmine administration to 50% restoration of the pancuronium 
depressed twilch tension) Bars represent means ± 1 SE Val­
ues m parentheses represent N 
from this metabolite than from pancuronium itself 
(Fig 1) Even though more neostigmine is required to 
antagonize the neuromuscular blockade from the 
other two metabolites, this should not represent a 
significant clinical problem since these metabolites 
are not very potent as neuromuscular blockers6 and 
are not present in concentrations as great as those 
observed with 3-hydroxypancuronium However, 
these conclusions should be viewed with some cau­
tion We determined the ability of neostigmine to 
antagonize the neuromuscular blockade produced by 
these metabolites when administered singly With 
prolonged administration of pancuronium, the neu­
romuscular blockade probably is a result of the com­
bined effects of pancuronium and all 3 of its metab­
olites We assume that since the neuromuscular 
blockade from pancuronium or one of its metabolites 
is easily antagonized, a blockade from a mixture of 
these compounds would also be easily antagonized 
by neostigmine 
Our present data suggest that muscle relaxants that 
are not very potent required significantly more neo­
stigmine to antagonize the resultant neuromuscular 
blockade For example, 17- and 3,17-hydroxypancu-
ronium are less potent than pancuronium6 but require 
more neostigmine for antagonism of their neuromus­
cular blockade Similarly, gallamine which is less 
potent than pancuronium or d-tubocuranne also re­
quires more neostigmine for antagonism of its neu­
romuscular blockade " Not only was more neostig­
mine required for antagonism of a 17- or 3,17-hy-
droxypancuromum neuromuscular blockade than 
that required for pancuronium, but the duration of 
antagonism was significantly shorter (Fig 2) Perhaps 
17- or 3,17-hydroxypancuronium has a greater affin­
ity for the cholinergic receptor at the postjunctional 
membrane than does pancuronium Although an at­
tractive hypothesis, binding constants for the metab­
olites have not been determined Perhaps these me­
tabolites inhibit acetylchohnerase This would result 
in more acetylcholine at the synaptic cleft, requiring 
more muscle relaxant to compete for the receptor 
before neuromuscular blockade is produced This 
explanation would explain the lesser potency of the 
17- or 3,17-hvdroxypancuronium metabolite Also, 
inhibition of acetylcholinesterase may limit the ability 
of added neostigmine to further inhibit acetylcholin­
esterase Obviously, the ability of these metabolites 
to inhibit acetylcholinesterase needs to be determined 
in order to explore this hypothesis further Lastly, the 
less potent muscle relaxants obviously require higher 
plasma concentrations to produce a given level of 
neuromuscular blockade Do the increased numbers 
of muscle relaxant molecules interfere in some way 
with the kinetics of neostigmine inhibition of acetyl 
Cholinesterase7 In any event, our observations" sug­
gest an inverse relationship between potency of mus­
cle relaxants and amount of neostigmine required for 
antagonism of neuromuscular blockade Additional 
studies are required to confirm the validity and mech­
anisms of the possible relationship 
In summary, significantly more neostigmine is re­
quired to antagonize the neuromuscular blockade 
produced by 17- and 3,17-hydroxypancuronium me­
tabolites than is required to antagonize the blockade 
produced by pancuronium or its 3-hydroxypancuro-
mum metabolites Since the 17 and 3,17-hydroxy-
pancuromum metabolites are not potent as muscle 
relaxants and apparently do not appear in large 
amounts, no clinical problems should result insofar 
as reversal of pancuromum-induced neuromuscular 
blockade is concerned 
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6.4. Analysis of drug combinations 
When two drugs are studied for their possible interaction, prob­
lems often exist in analysis and graphic presentation of the results. 
To overcome this problem, the concept of isoboles and isobolograms 
was developed (Loewe 1953, 1959). With this method, discrimination 
between synergistic, antagonistic, and summative (additive) inter­
action is possible. Isoboles are principally connecting lines bet­
ween equipotent doses of compounds A and В and their combinations. 
To explain the theoretical fundamentals of this method, we will con­
sider 3 extreme interactions. First a pure summation, second a pure 
antagonism, and third a pure synergism. 
Pure Summation 
Dose response curves for equipotent compounds A and В are drawn 
m a rectangular system (fig. 1). Suppose they interact purely sum-
matively. Then two molecules of A plus two molecules of В will have 
the same effect as four molecules of either A or В and so on. The 
dose response curves for these combinations will thus form a sail of 
lines that are in one plane (fig. 2). 
Equipotent combinations can be connected by a straight line. 
This line can be drawn as an isobole in an isobologram (fig. 3). 
•
DA 
Figure 1. Dose response curves for compounds A 
(OA) and В (OB) in one rectangular system. 
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Figure 2. Dose response curves for compounds 
A (OA) and В (OB) and their combinations when 
purely summative. Equipotent combinations 
can be connected by a straight line (CD). 
Figure 3. Isobologram for dose re­
sponse curves from fig. 2. 
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Pure Antagor.isrr 
When a theoretically extreme pure antagonism exists between 
the two compounds, their combinations will behave differently. 
The individual drugs will give dose response curves as in fig. 1. 
Suppose they are equipotent, i.e. one molecule of drug A has the 
same effect as one molecule of drug B, and further, that one mole­
cule of A can antagonize one molecule of В completely, and vice 
versa. When equimolar doses are administered, the dose response 
curve for the combination will then be in the plane of zero effect 
(fig. 4). 
For simplicity, we consider the other combinations to be in 
two flat sails. Only in the zero effect plane will all the dose 
response curves have a common isobole. Plotted in an isobologram, 
it will be presented as a line to the far end (fig. 5). At other 
levels, only part of the combinations can be connected by isoboles 
which are in the isobologram rectangular to the X and Y axes. 
When the antagonism is not that extreme, i.e. the combination 
dose response curves are not presented in two rectangular sails 
and the equimolar combinations are not in the zero effect plane, 
they form a curved sail (fig. 6). 
The isoboles are then curved lines in the isobologram (fig. 7) 
ligure 4. Theoretical dose response curves 
for extreme antagonistic-acting Compounds A 
and В and their combinations. 
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Figure 5. Isobologram for fig. 4 when equi-
potent antagonistic doses are considered in 
the zero effect plane. 
Figure 6. Dose response curves for compounds 
A and В «hen an antagonistic interaction is 
present. Equipotent points are connected by 
an isobole (CD). 
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Figure 7. Isobologratn for dose response 
curves from fig. 6. 
Pure Synergism 
With t h e o r e t i c a l l y extreme s y n e r g i s t i c d r u g s , t h e combinat ion 
of t h e s m a l l e s t amount of compound A wi th t h e s m a l l e s t amount of 
compound B, maximum e f f e c t a l r e a d y e x i s t s . In t h i s c a s e , t h e ex­
treme dose r e s p o n s e curve i s i n f a c t t h e E f f e c t a x i s ( f i g . 8 ) . The 
i s o b o l e for a l l t h e o r e t i c a l c o m b i n a t i o n s , t h e n , i s in t h e p l a n e of 
compound A and B. 
Figure 8. Theoretical dose response curves for 
compound A and В when an extremely synergistic 
interaction exists. Equipotent points are con­
nected by an isobole (CD). 
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Plotted in an isobologram, it will be the X and Y axes (fig. 9) 
CD* •DA 
Figure 9. Isobologram for fig. 8. 
When t h e o r e t i c a l l y l e s s s y n e r g i s t i c combinat ions a r e used, t h e 
dose r e s p o n s e curves for t h e combinat ions w i l l form a curved s a i l 
( f i g . 10) wi th a concomitant i s o b o l e t h a t can be p l o t t e d i n an 
isobologram ( f i g . 1 1 ) . 
Figure 10. Dose response curves for compounds 
A and В and their synergistically interacting 
combinations, with an isobole (CD). 
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Figure 11. ibobologram for fig. 10. 
In conclusion, we ca 
less synergistic the inte 
isobolograms approach the 
tion (fig. 12). Presenta 
grams, therefore, clearly 
action between two drugs. 
combinations are studied, 
only one point, as is the 
raaining chapters, we used 
results of our interactio 
η say that the less antagonistic or the 
raction of two compounds, the more their 
straight line that exists at pure summa­
tion of experimental results in isobolo-
demonstrates the characteristics of inter-
Since most of the time not all possible 
but only a few, isobolograms will contain 
case in our following studies. In the re-
the isobologram technique to express the 
η studies. 
Figure 12. Isobolograns for ant agonis Lie, 
synergistic, and summative interacting 
combinations of compound Λ and B. 
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s Potentiation of neostigmine and pyridostigmine by 
4-aminopyridine in the rat 
RONALD D MILLER*, PETER A F DENNISSEN, FRANCIEN VAN DER POL, SANDOR AGOSTON, 
LEO HD! BOOII AND JAN F CRUL 
Institute of Anaesrhesiolngy, Catholic Uimersiry, hijnieçen, The Netherlands, and Institute of Clinical Experimental 
Anaesthesia and Clinical Pharmacology, State Unnerut) of Groningen, Groningen, The Netherlands 
The interaction between 4-aniinop>riJine and neostigmine or pyndosligminc was studied 
in vivo in ihe rat sciatic nerve-anterior tibialis preparation using the constant infusion of 
paiiLuronium ІесЬпісціс The ED50 (dose of drug which produced a 50" antagonism) of 
neostigmine, pyridostigmine and 4-aniinopvridine were 18, 49 and 440 /ig kg ' rcspcctivelv 
T h i a Idi'ioT of 10) (ig kg ' of 4-a'Tiinopyridiiie, which prodjwcd no antagonism b> itself, 
decreased the neostigmine LD^O to 7 4/ig kg ' The idditionof 200 / « kg ' of ¿l-aminopynd-
ine, which produced a 10 ^ an'agomsm bv itself decicased the FD50 of pjndosligmine to 
II /ig kg ' We conclude that both neostigmine and pyridostigmine interact with 4-amino-
pyrine svnergistically 
Neostigmine and pyridostigmine arc used clinically 
to antagonize a neuromuscular blockade produced 
by pancuronium or ( ) lubocurarme (Miller, 1976) 
Neostigmine and pyridostigmine act primarily by 
inhibition of acetylcholinesterase Recently, 4-
aminopyridme has been used clinically as an antagon-
ist of ( Vtubocurarme (Sloyano\, Vulehcv & others, 
1976). However, the mechanism of this antagonism 
differs from that of neosticmmc or pyndostismme 
4-Ammopyridine docs not inhibit accly(Cholin-
esterase activity (Molgo,Lemeignan & Leehat 1977), 
but increases the amount of ncctvlehohnc released 
by the motor nerve terminal in response to a nerve 
impulse (Bowman, Harvey &. Marshall, 1977, Molgo 
& otheis, (977) Since neostigmine or pyrido-
stigmine antagonize a pancuromum-induced neuro-
muscular blockade b> a dnTcrent mechanism from 
(hat of 4-aminop) ridine, и с propose that these agents 
may not act in an additive manner We tested this 
possibility in the following study 
METHODS 
Eighty-five rats, 260 to 430 g were anaesthetized with 
pentobarbitone, 40 mg k g - 1 and urethane, 500 mg 
kg - 1 , intrapentoncally Both jugular veins were 
cannulated and all drugs were administered through 
these cannulae A cannula in the caroud artery per­
mitted transduction of arterial blood pressure A 
tracheostomy was performed and ventilation was 
controlled with a Braun air pump The tendon of the 
* Correspondence Department of Anesthesia Uni­
versity of California, San Francisco, California 94143, 
U S A 
•Work performed while Doctor Miller was a visiting 
professor at ihe above institutions 
left tibialis anterior muscle was freed, sectioned and 
connected to a Grass FI01 force displacement trans­
ducer The resting tension was adjusted to 20 g 
Stimuli of 0 2 ms duration and of strength sufficient 
to produce a mavimal twitch were applied to the 
sciatic nerve through a bipolar electrode at a frequency 
of 0 1 Hz Tu itch tension was recorded on a poly­
graph Ree al and muscle temperatures were main-
tan.ed between 37 and 38° 
Pincuromum was administered indavcnously by 
continuous infusion to achieve and maintain 9 0 % 
depression of twitch tension When the mlusion rate 
required to maintain 90 V, dcpicssion of twitch ten­
sion was constant for at least 15 mm, neostigmine, 
pyridostigmine or 4 aminopyridme or a combination 
of these urugs was given as an intravenous bolus 
Except when 4-aminopvridinc was given alone, 
atropine 17 /ig kg ' w ,s given intravenously before 
administration of drugs (see Miller, Van Nyhuis & 
other,, 1974 for technique) Time from antagonist 
administration to peak effect (onset), magnitude of 
antagonism, and time from antagonist administra­
tion to 50% return to the paneuronium-depressed 
twitch tension (duration) were calculated Only one 
dose of antagonist or combination of antagonists was 
studied with each animal 
Initially, dose-response curves were determined 
for neostigmine, pyridostigmine and 4-aminopyridine 
alone Then neostigmine or pyridostigmine was 
combined with various doses of 4-ammopyridine to 
determine whether these drugs interact with each 
other in an additive or synergistic manner Specifi­
cally, dose response curves were determined for neo­
stigmine with 4-aminopyridine 100 /¿g kg - 1 and for 
60. 
pyridostigmine with 4-dminopyridine 200 μg kg ' 
Dose response curves were determined for 4-amino-
pyndine with neostigmine 3 5 and 7 S jag kg ' and 
with pyridostigmine 25 ^g kg - 1 The dose response 
curves were compared by anjK sis of variance 
k g - 1 of 4-aminopyridine decreased the ED50 of 
pyridostigmine Trom 49 to 11 μg k g - 1 (big 3) 
Addition of 3 5 and 7 5 μβ k g - 1 of neostigmine 
decreased the ED50 of 4-ammopyridine from 440 to 
RFSULTS 
The ED50 (dose of antagonist which produced a 
50% antagonism of the pancuromum-depressed 
twitch tension) of neostigmine, pyidosligmine and 
4-aminopyridinewcre 18,49and440¿igkg ' (F ig 1) 
100 
50 
75 30 100 200 ¿00 ΘΟ0 
FIG 1 Correlation between dose (^g kg ') (abscissa) of 
neostigmine (NS), pyridostigmine (PS) and 4-amino-
pyridme (4-AP) on 0 0 antagonism (ordinate) of the 
pancuromum-depressed twiich The lines represent 
analysis of linear regression The vertical lines represent 
the mean it s e in four rats 
The dose response curves did not significantly deviate 
from parallelism The 1200μg k g - 1 dose of 4-ammo-
pyndme caused generalized twitching of all muscles 
which resembled convulsive activity in spite of the 
animal being anaesthetized with pentobarbitone 
This dose was not included in the calculations 
because it caused no more antagonism than did the 
800 μg kg"1 dose Addition of 100 μ ε kg" 1 of 4-
aminopyndme decreased the ED50 of neostigmine 
from 18 to 7 4 μg kg ' (Fig 2) Addition of 200 μg 
uu-
50-
1 
Τ ν 
/ 
10 25 50 100 
Fie, 3 The effect of pyridostigmine alone ( - ) and given 
with 4 aminopyndine (200 ^g kg - 1 , ) on % 
antagonism (ordinate) of the pancuromum-depressed 
twitch The lines represent analysis of linear regression 
The vertical lines represent the mean ± s e of four rats 
Abscissa Pyridostigmine (ng kg ') 
220 μg kg ' and to 82 μg kg ' respectively (Fig 4) 
The ED50 of 4-aminopyridine also was reduced 
from 440 μg kg ' to 76 g kg-1 by pyridostigmine, 
25 μ 6 kg · (Fig 5) 
The ED50 values of the various combinations of 
4-aminopyridinc plus neostigmine or pyridostigmine 
were plotted against an isobologram constructed 
from the hD50 values of the drugs alone Either 
combination produced an effect greater than simple 
addition (Fig 6) 
When equivalent levels of antagonism are com­
pared, 4-aminopyridmc increased the onset times but 
not the duration of action of neostigmine (P < 0 05) 
uu-
50- 1 
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FIG 2 ThecfTectorncostigniinealonei— -)andgivcn 
with 4-aminopyridine (100 ^g kg 1 ) on 0n 
antagonism (ordinate) of the pincuromum-deprcssed 
twitch The lines represent amlysis of linear regression. 
The vertical lines represent the mean l s c of four rats 
Abscissa Neostigmine (/ig kg ') 
100η 
50 
i"í 
70 100 200 250 400 Θ00 
FIG 4 TheefTect οΓ4 aminopyndine alonc(-)andgiven 
with neostigmine ( 3 5 MS kg ' - - - 7 5 ng 
kg ') on " , antagonism (ordinate) of the pancuromum-
depressed twitch I he lines represent analysis of linear 
rccression The vertical lines represent the mean £ s e 
ot lour cats Abscissa 4-aminopyridinc (^g kg ') 
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-.00 Ί 
50 
50 100 200 400 800 
H G 5 The cITcLt οΓ 4 aminopvndmc ahme ( ) and 
given with р\гкІоч1і£тіпе (2^ /'g kg ' -) on '( 
andtagonism (onhnaie) of the pain-jronuini-deprLsseil 
twitLh The lines repiesent anaKsis o\ linear reuression 
The vcrtiLdl lines represent the mean se lor lour rais 
Abseissa 4 Λιηιηορ\ridine (^g kg ') 
oO 
I'/: 
(Fig 7A) In contrast, 4-jminop>riclinc had no 
effect on cilhcr the onset times or duration of 
pyridostigmine action with one execption (Ι ι с 7B) 
The pyridostigmine 10 /tg kg ', pliis4-ammop\ridine 
200 /¿g kg - 1 combination had a loniiu onset lime 
than pyridostigmine alone (Ρ OOM (| ig 7H) 
Blood pressure uas not changed by the above 
drugs alone or combinations 
DISCbSSlON 
4-Aminopvridinc potentiated the effect of neostig­
mine or p\ridostigmine (F ig fi) That is. (he effects 
of the neostigmine or pyridostigmine and 4 amino-
pyndine combinations were greater than would have 
been predicted from the effects of the drugs given 
alone An effect other than simple addition might 
have been predicted from the fact that 4-amiiio-
0 : o fco 
•"RGISM 
100 200 300 
ι SYNrSGISM 
i „ 1 
100 200 300 
FIG 6 Correlation of the FD^Ofdose which produced a 
50'n antagonism of the pancuionmni depressed tvMieh) 
ol 4-атіпор гкІіпс, neostigmine and pyridost gmine 
alone Irom which the line of identnv was lornicd The 
dots represen! the \ ΙΉΟ of апоиь combinations ofthe 
abo\c drugs Ordinate μ% kg ' AbiCissa 4-Amino-
pyndmc (μ% kg ') 
Fu· 7 Correlanon helween time (mm) (abscissa) and 
' antagonism (oidmate) ol the pancuionium-dcprcssed 
twiteh \wili neostigirme (NS) (λ) or pyridostigmine 
(PS) ([)) alone and wiih 4-amin ip\ridine (4 ЧР) Ihe 
mnnbers beside Ihe drug abbreviations are the doses in 
/<g kg ' 
p\ ridine has a dînèrent mechanism of action from 
neostigmine and pvndostigmme. 4-Aminop>ridine 
antagonizes a neuromuscular blockade by iiKreasing 
both evoked and spontaneous release ot acetylcholine 
from the motor nerve terminal rather than by 
inhibition of acetyleholinesterase (Bowman & 
others, 1977) 
Neostigmine and pyridostigmine are drugs usually 
used to ant igom/ea non-depolari/mg neuromuscular 
blockade (Miller. I976) However, 4-атіпоругкІіпе 
mav offer some advantages The apparent absence 
of muscarinic cITccls eliminates the need for con­
comitant administialion ol atropine as is required 
with neostigmine and pyridostigmine (Fogdall & 
Miller. 197Я) In fact, recently, 4-aminopyridinc has 
been shown to have some svmpatbetic activity It 
potentiated responses of the adrenergicallv innerv­
ated rabbit vas tlelerens io transmural stimulation by 
causing mei eased noradrenaline release (Johns, Golko 
& others, I97fi) Also, 4-aminopyridine increased 
both evoked and spontaneous release of adrenaline 
Irom the portal vein (1 cander, Arncr & Johansson, 
1977) Despite this evidence for sympathetic stimula­
tion, the blood pressure in this study was not altered 
by administration of 4-aminopyridine 
Anoilwi advantage ol 4-aminopyridine is that it 
will antagoni/c an antibiotic neuromuscular blockade 
62. 
where neostigmine and pyridostigmine arc often 
ineffective (Bikhazi, Burked & others, 1977) With 
these advantages, perhaps 4-aminopyridinc should 
be used alone rather than in combination with neo-
stigmine or pyridosugmmc Ho\ve\er, 4-ammo-
pyndinc readily crosses the blood brain barrier 
Doses of "t-jminopyridme which completely antagon-
ize a non-depolan/ing neuromuscular blockade 
cause central nervous system stimulation which we 
observed with the 1200 /¿g kg ' dose, the precise 
relation between dose and central nervous system 
stimulation needs to be defined Perhaps the 
combination of neostigmine or pyridostigmine plas 
4-aminopyridine will attenuate or eliminate the dis-
advantages of these drugs indiviuually That is, the 
dose of 4-aminopyridine will be low enough not to 
cause central nervous system stimulation, yet may 
reduce the doses of neostigmine or pjridostigmme 
sufficicnlly to attenuate or eliminate the need for 
atropine to prevent muscarinic stimulation. Also, 
perhaps the combination of neostigmine or pyrido-
stigmine plus 4-aminopyridine can be used to 
antagom/c the anlibioiie-induced ncuiomuscular 
blockades where neostigmine or pyridostigmine 
alone often fail (Miller, 1976) 
7 he above advantages of the drug combination arc 
specularne and need further studs That 4-amino-
p>ridine markedh enhances the ahilnv of neostig-
mine oi pyridostigmine to antagom/c a pancuron-
ium neuromuscular blockade needs confirmation in 
other species including man 
Ack now It dut ment s 
The authors gratefully acknowledge the editorial 
advice of Dr Edmond I Fgcr, II and Dorothy 
Urban 
RrFbRFNCFS 
BIKIIA/I G B.BLRKirr L KFLIY Ρ WIRTA, M & J-OLDLS, h (1977) Abstracts of Scienlnic Papers, American 
Society of Anestheìiotogittì, pp 461-464 
BOWMAN W С Hutv iv .A L & MARSIIAI I I G (1977) Naunui ЧтіеасЬегі·* Arch Phannac 297,99-101 
FOGDAIL, R Ρ & MILLI R . R D (1971), Aneulu uofoçi, 39 504 W 
JOHNS A Goi ко, D S , LASZON Ρ А Л PVION D M (1976) tur J Phannac , 38, 71-78 
LLANDLR, S , Акчік A & JOHANSSON В (19771 //ж/, 46 351-361 
MlLLLR R II (1476) Amsllieuolo"! 44 1ІЯ-12Ч 
MILLLR, R D . V A N N Y I I I I S L S l GIR, 1 I II, VITFZ, Τ S & WAY, W L (1974) Ibid,41.Π 33. 
MOLGO, J , 1 ΐΜίκ,ΝΛΝ, M & I к НАГ Ρ (1977) J РІыппас i \р Vier , 203 651 661 
STOYANOV.F VLLCHIV, Ρ , SiirCRiravA, M & MARINOVA, M (1976) Aiuiesth Reuu Inlen Ther , 4, 139-142 
63. 
^NFSTHLSIOLOCY, Vol 50, \o 5, Mny 1979 
6.6 4-Aminopyridine Potentiates Neostigmine 
and Pyridostigmine in Man 
Ronald D Miller, M D ,' Leo H D J Βοοη, M D , t Sandor Agoston, M D . Ph D ,% Jan F Cru! M D . Rh D § 
To eluiidate the interaction of 4*aimnop\ridine with neoslig-
mine and pvndosligmine. the authors studied 57 anesthetized 
surgical patients using a technique of constant infusion of pan­
curonium to quantitate antagonist ac(i\it\ •1-Λπιιπιιρ\ ridine. 0 15 
orO 35 mg kg. produced no antagonism while 0 5 mg kg produced 
a mean 24 * 6 per cent (peak) antagonism I he dose that produced 
50 per ceni antagonism (t D ,) of neostigmine alone nas 22 μ% kg, 
with 0 35 mg'kg -4-am ι пору ridine, к nas 7 Mg kg The t D j of 
pyridostigmine alone was I IO Mg kg, with 0 35 mg kg 4-
aminopyndine, it was 27 Mg'kg 4-Aminopvridine prolonged the 
onset times of both neostigmine and pyridostigmine, but 
prolonged the duration of action of neostigmine only At a 
given level of antagonism of pam uron<um, adding -l-ammopvri-
dine 0 35 mg'kg, to neostigmine and to pv ndosligmine decreased 
the amounts of atropine needed to prevent a change in heart ratebv 
68 and 70 per cent respectively The authors conclude that 4-
aminopyndine potentiates antagonism of a pancuronium-mduced 
neuromuscular blockade by neostigmine or pyridostigmine Also, 
less atropine is needed to prevent cardiac muscarinic stimulation 
when 4-arninopyridinc is used with either neostigmine or 
pyridostigmine (Key words Antagonists, neuromuscular relax­
ants 4-aminopvridine, neostigmine, pyridostigmine Muscle 
relaxants pancuronium Parasympathetic nervous system atro­
pine ) 
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p\r ¡dosi igni mt Pul un mai \ obsei \.itions in man'and 
sludies in animals'1 ' show no mustannit ei led ol 4 
ainiii(ip\ ι idmi In lau 4 ашшормкіше lias leieniK 
ht m shttun io ha\i sMiipalheiii .iiti\H\ li fMHentiated 
iis |)onsis o( ibi adii пет gic all ν ι η nei \atid lahhil 
\as di It it us to nansimnal sinnulalion hv tatising 
nou pini pin nu i ikas i * and m o east d bol h ivoked 
and spon l.nu ous к li asi- of noi ерик pilline (toni the 
pottal \ i in ' ' \lso 4 aininopvi idme aniagoni/es ihc 
neumimist ul.n blockades pioduted hv most andbi-
otics ^ l nloi tunatilv the dosis ol 4-aminopvt idme 
ni ι essai ν loi loinpliic antagonisin ( >1 mg/kg) also 
stimulate ι IR CI tu κι I nei \ ous s\siem and cause 
posiopt ι at ivi iistkssniss and conlusion ^unpublished 
dat.ι S \gi>ston) 
We leieniK obser\ed s\nergisni between Ί-
auitnopv ι idine and neostigiiunc οι pvi idostigtinnc 
in iaisH Suib svneigism m man could dei ι case the 
dose ol neosligmini oi p\ridosligitiinc ncccssdr\ (or 
aniagonism and thetebv atienuaie oi even eliminate 
iht need (oi concomitam administiation oí atropine 
In tht (Usctibcd heiein stud) we deinonstraied that 
svneigisni dois ociut and that the icqunement for 
ali opini is lonioniuanth deireased 
Methods 
biliv-sevcn tonsenimg suigical patients, ASA Class 
I oi II wtie studied intraopcralivclv fhev were 43 
± 7 (S D ) \eais oí age and 74 ± с) kg in weight I hey 
leceived an opine, 0 2 J mg diopendol, 5 mg, and 
pintiamide (a narcoiic analgesu), 11 In mg im, ap-
pioMinaiek an bout prior io anesthesia '\nesihcsid 
was induced with thiopental. 1 τ to 2 0 mg/kg.gamma-
hvdtowhuivi к and 50 mg/kg. and lentanvl, I ~> μψ,Ι 
kg i\ ( ontrolled venidaiion kepi end-tidal carbon 
dioxide comenitation Ыч ееп 4 and г) pet tent 
I hiougb 2[ï-gauge needle elei nodes, we delivered 
suptamaxinial st|uare-wa\e i)ipolar pulses of 0 1 rnset 
duratioti at 0 I H/ to the ulnar nerve at the wrist I he 
resultant l o u t of thumb adduition was i|uantitated 
with a force-displaiement transduier and reiorded 
«)n a pokgraph 
A teihnicjue of tonstanl infusion of pancuronium to 
r
 Bikha?! (.B Burkiu 1 Kilk 1' d a l I hi iniciatnon of ¿mi 
hint us I mbiKiii.ii nil and -1 anunnpviidiiu' at the nruroimiii ular 
juiuuon Abst rails Annual Mctun^ nf tin Anuí к an StKielv nf 
XnisilitsmlngiMs |Ч7(і pp 464-404 
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nu.in - ] Sh di \ i luts Idi i l i i 
4.I11S І І Ц 
M i К Hls 
-с 50 ¡J 
1 
PSatore 
20 
Dose ÍAjg/kg) 
75 120 200 
í|uanin.ue ли. immis i а с і і м п was used loi all siiidios '' 
A l i c i a holtis ι η jet non n i pam n i n n i l i m, !20 ^ g ' k g . η , 
p a i K u i n n i u m , 200 ¿ig/inl. v\as mlusi 'd contmuoiisK 
i i o m .ι p u m p in p t o d u t e a (onsiant 40 poi ceni <lf-
picsMon ol i w i u II fensinii 1 he tau- u r r d c d (кч it-ascd 
pmgH'ssiM'K lo i iht' нем 1")-1Ί m i n . a l ic i w h u h 
il r emani t'd i o t i stani, as dei ci mined h\ al Icasi Ι Ί min 
oí nbsci а і н ш With t i n pam i i i n n i u m і п і и м п п t n n -
l inucd ai this ι aie, ι he antañónisi u.is ці еп as bolus, ι\ 
I he icsul ia i i i ш а ч ш ш ш ania^onisin ol i w i u h dc-
picssion uas i c t o i d c d and piescnicd as a ]Х'нспіаі;е 
o l the ptt '-c\ iMinj i 40 pei ( c u i i lepiession (/ ц , a peak 
i n n ease lo 00 pei <cni dcpicssioi i ol ι he ( o n t i o l t w i u h 
lensiun Ix ' lo ic p a m u t o n i u m would bc ( a l t u l a i c d as 
(90 - Ы)) 100/00 οι 3;ì pei ι cui antagonism) In 
addi t ion, we incasuicd unies ( к и п а п і а ц п і т і admi i i-
ist iation lo 50, 70 and 100 pei t e m ol peak ei l e t i 
(onset t ime) and 70, 50 and 30 per tent l e i i i r n io 
ihe p a m u r o n u i n i - i n d u c e d depiesscd tvMiih tension 
(durat ion oí a<tion) Details oí these cakukinons 
have been described 9 
Dose-iesponse tu ives и е і е determined lo i neo­
stigmine, pvi idosi jgnune, and 'l-aininnpvt id me alone 
Dose-1 espouse ( u n e s wei e (hen dolc i mined lor 
neostigmine and pvi idosl igmine in the píeseme ol 
4-anunopv ι idine, 0 'УУ mg/kg Dose-iesponse tu ives 
also were d e t e i m i n e d lo i 4-ammopvt id ine m ihe 
presence oí neostigmine 7 "i ¿¿g'kg, oi pvi idostignune 
40 Mg/kg Oulv one dose o l aiuagomsi o? aniagoiusi 
mixture was studied in eath patient 1 he dose of 
antagonist thai prod I H ed "lO pei tent antagonism 
( t D^D) was dei ived h o m turvesdetonninet l by analvsis 
of l iu ta i logiossion I ho ( inves ue ie comp.ued ί ο ι 
paial lcl isin and siti l i In analvsis o l t o v a n a n t e I ho 
oust i limes and il in at ion o l a d ion wen· ι о т pai od In 
/ It si h» unpai iod dala 
l'alionis who teceivod neosiigmuio tu pvndost ig-
i i i ine .done wei e .liso given au opino. 0 5 mg i\ I hose 
viho i t i e i v e d J-amniopvi i i lme alone wen noi given 
а п о р и ю I l luse vi ho lotoivod the m i M u i e s o l neo-
si ignu ne oi pvndosi igni ine with 1-a mi nopv r id ine 
vicio given a l i n p i m . 0 'i') mg \ n addit ional 0 2"» mg 
.il top ine was given lot cv ei ν 10 beai/min dtctease m 
hcai ι tato m an ν pat it tit I he total amount ol all opine 
given was t a l t u l a i o d I he anion η ι o l . inopiné needed 
with o.uh dose o l aniagomst was plotted against the 
peu etuage o l antagonism thai dose ol antagonist 
p i od ut od 1 he al ι opino lequuemenis w eie (hen t o t n -
p a i c d In analvsis oí vanante 
Results 
We did noi t o n s i l l i t i a dosc-tesponse t u i v e toi 
4-amiriopv ι idine alone because neilhet 0 I T (n = 4) 
noi 0 'ì"> mg'kg (η = S) 4-aniino|)vi idine ant.igoni/ed 
the pant u i o n i u m * indue ed depiession o l twitt h 
lension, hut 0 5 mg/kg (n = 4) p i o d u t e d 21 ± β pei 
cent antagtimsm I he tloses ol neosiigmmo and p v i ­
idosl igmine ι hal p i o d u t e d ΊΟ pei t e n i antagonism o l 
the p a n i u t o n i u m - i n d u t e d dopi essimi o l l u i t t h (l· DV)) 
weie 22 and 1 K ^ g ' k g lospettivolv (hg 1) I h e a d c h -
tion ol 4-aiiunopv ur l ine, 0 45 tng/kg, detreased ι he 
l· І) ,ч of neosiigmine and pvr idosi igmine io 7 and 27 
¿tg/lsg. lespet uveU (P < 0 01) (hg 1) I he cui ves did 
not deviale f m i u paiallelism 
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6.7. Comparative reversal of pancuronium by neostigmine, edrophonium, 
4-aminopyridine and their combinations in cats 
Leo H.D.J. Booi], M.D., Ronald D. Miller, M.D., and Yung J. Sohn, M.D. 
Submitted to Anesthesia and Analgesia 
Introdw^ion 
Since the introduction of neuromuscular blocking agents m 
anesthesia, problems concerning their reversibility have existed 
(Miller 1976). For reversibility of nondepolarizing neuromuscular 
blocking agents, the cholinesterase-mhibiting drugs neostigmine 
and pyridostigmine are adequate. However, these drugs show unde­
sirable muscarinic side effects, and can usually not reverse anti­
biotic or antibiotic-nondepolarizer-combined blockades. The ability 
of 4-aminopyridine to antagonize neuromuscular blockade was des­
cribed m a recent study (Stoyanov et al. 1976). In a previous 
study we showed that with dosages that can safely be used in patients, 
4-aminopyridine does not reverse deeper neuromuscular blockades 
(Miller et al. 1979). However, these low dosages of 4-aminopyridine 
potentiate neostigmine or pyridostigmine in a synergistic manner 
(Miller et al. 1978; Miller et al. 1979). A lower dose of neostig­
mine or pyridostigmine is thus needed to adequately reverse the 
pancuronium blockade. Less severe muscarinic side effects occur, 
as measured by the atropine requirement (Miller et al. 1979). In 
vitro studies showed that 4-aminopyridine can antagonize neuromuscu­
lar blockades induced or augmented by antibiotics (Burkett et al. 
1979; Singh et al. 1978), as confirmed in man for lincomycm (Booi] 
et al. 1978), and in cats for polymyxine В (Lee et al. 1978); The 
onset and duration of action of neostigmine in combination with 4-
ammopyndine are prolonged compared to the onset and duration of 
action of neostigmine alone (Miller et al. 1978; Miller et al.1979). 
Since edrophonium is known to have a rapid onset of action, we 
investigated whether its combination with 4-aminopyridine or neo­
stigmine would be preferable to the combination of neostigmine and 
4-aminopyridine. Edrophonium shortens the time of onset, while 4-
ammopyndine prolongs the duration of action. The interaction 
between neostigmine and edrophonium is also included in this study. 
Me thods 
Cats of either sex weighing between 2.5 and 4.2 kg were anes­
thetized with a-chloralose, 60 mg/kg and urethane, 250 mg/kg, intra-
pentoneally. Both external jugular veins were cannulated for ad­
ministration of all drugs. A cannula in the left carotid artery 
permitted continuous registration of the arterial pressure. A 
tracheostomy was performed, and ventilation was controlled with 
room air by a Harvard respiration pump. The temperature was kept 
constant at between 37 and 380C. The tendon of the left tibialis 
anterior muscle was freed, sectioned, and attached to a force-dis­
placement transducer. Supramaximal square wave stimuli were applied 
to the ischiadic nerve at 0.15 Hz and a duration of 0.2 msec. TWitch 
tension and arterial pressure were recorded continuously on a poly­
graph. Pancuronium was administered as a bolus, followed by a 
continuous infusion, in order to keep the twitch depression at a 
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constant level of 90%. When twitch depression and infusion rate 
were constant for at least 30 minutes, a dose of neostigmine, 
edrophonium, 4-aminopyridine, or one of their combinations was 
administered. Magnitude of recovery, onset time (time from injec-
tion until peak effect) and duration of action (time from injection 
until 50% return of the original twitch depression) were calculated. 
When the twitch depression had returned to its original level for 
at least 45 minutes, the next dose of the same drug or combination 
was administered. The sequence of dosages was randomized. Linear 
regression analysis of the data points resulted in dose response 
curves, and a general linear test approach for testing the inequali-
ty of neostigmine and its combination with 4-aminopyridine was per-
formed. An analysis of covariance was done to demonstrate differ-
ences between edrophonium and its combinations. Analyses of variance 
for both onset time and duration of action with equipotent doses were 
done, followed by a multiple comparison method (Neter et al. 1974). 
In an additional group of cats, combinations of equipotent doses of 
edrophonium, neostigmine, and 4-aminopyridine were administered 
(EDgo's) to confirm the validity of the results. 
Results 
A total of 35 cats were studied (table 1), from which dose 
response curves were obtained for neostigmine, 4-aminopyridine, and 
neostigmine plus 4-aminopyridine 15 yg/icg (fig. 1), and for edrophon-
ium, edrophonium plus neostigmine 10 |jg/kg, and edrophonium plus 4-amino-
pyndine, 150 yg/kg (fig. 2). Neostigmine was significantly differ-
ent from neostimine plus 4-aminopyridine (p<0.001), but the dose 
response curves did not deviate from parallelism. The combinations 
of edrophonium plus neostigmine and edrophonium plus 4-aminopyridine 
were not different from edrophonium alone (p<0.867). The response 
of edrophonium showed a ceiling effect. 4-aminopyridine interacted 
synergistically with neostigmine (fig. 3), resulting in a decrease 
of the ED50 for neostigmine from 15.9 pg/kg to 5.0 pg/kg. The inter-
action between edrophonium and both neostigmine and 4-aminopyridine 
was antagonistic (fig. 3). When equipotent doses were considered, 
the onset time of neostigmine plus 4-aminopyridine was not different 
from the onset time of neostigmine alone (p<0.96). The onset time 
of the combination of edrophonium and 4-aminopyridine was, however, 
Table 1. Number of cats studied in each group. 
number of cats drug administered 
5 neostigmine 
4 edrophonium 
4 4-aminopyridine 
6 neostigmine + 4-aminopyridine 150 ug/kg 
4 edrophonium + 4-aminopyridine 150 ug/kg 
6 edrophonium + neostigmine 10 yg/kg 
3 edrophonium 150 yg/kg + neostigmine 20 yg/kg 
3 edrophonium 150 yg/kg + 4-aminopyridine 300 yg/kg 
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Figure 1. Dose response curves for neostigmine, 4-aminopyridine, 
and neostigmine plus 4-aminopyridine 150 yg/kg in cats under 
a-chloralose-urethane anesthesia (·-·: neostigmine; X—X: 4-araino-
pyridine; о—o: neostigmine plus 4-aminopyridine). 
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Figure 2. Dose response curves for edrophonium, 
edrophonium plus neostigmine IO pg/kg, and edrophon­
ium plus 4-aminopyridine 150 Ug/kg in cats under 
a-chloralose-urethane anesthesia Ç— ì edrophonium; 
·—·: edrophonium plus neostigmine; X—x: edrophonium 
plus 4-aminopyridine). 
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Figure 3. Isobolograms for the ED^Q of neostigmine, edrophonium, 4-amino-
pyndine, and their combinations. 
significantly prolonged compared to the onset time of edrophonium 
and the combination of edrophonium and neostigmine (p<0.003) (fig. 
4). The duration of the neostigmine plus 4-aminopyridine combina-
tion was significantly prolonged in comparison to neostigmine alone 
(p<0.005). Also, the duration of action of edrophonium in combin-
ation with 4-aminopyridine was longer than edrophonium alone (p<0.002), 
while there was no difference in the combination of edrophonium with 
neostigmine (p<0.233). When neostigmine alone or m combination 
with edrophonium was administered, atropine was required to keep 
the arterial pressure unchanged, with neostigmine alone, 8 yg atro-
pine per 100 vg neostigmine was needed, wmle with the combination 
4 \ig atropine per 100 yg, neostigmine plus edrophonium was required. 
When neostigmine was administered in combination with 4-aminopyri-
dine, no atropine was required at all, as was the case with edro-
phonium alone or m combination with 4-aminopyridine. 
Disaussion 
The synergistic interaction between neostigmine and 4-ainino-
pyndine is in accordance with our earlier studies in both rats and 
man (Miller et al. 1978; Miller et al. 1979). It results in all 
these species in a decrease of about 65% of the ED50 for neostigmine. 
A possible explanation for this synergistic interaction is that 4-
aminopyndine increases the acetylcholine release (Bowman et al. 
1977; Molgo et al. 1977), while neostigmine inhibits the Cholines-
terase activity. These together result m more acetylcholine being 
available than with either drug alone. If the main effect of edro-
phonium were an increase in acetylcholine release, as has been pro-
posed in the past (Blaber et al. 1959; Blaber 1972), additive inter-
action would be expected in the combination with 4-aminopyridine, 
and a synergistic interaction in combination with neostigmine. If 
its main effect were the same as neostigmine (Smith et al. 1952; 
Nastuk et al. 1958), i.e. Cholinesterase inhibition, an additive 
interaction with neostigmine and a synergistic interaction with 
4-aminopyridine would be expected. However, if its main effect is 
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Figure ^. Time to peak effect and duration of action 
until 50% return of the depressed twitch tension for 
equipotent doses of neostigmine, edrophonium, ¿t-amino-
pyndine, and their combinations (1: neostigmine 20 
Pg/kg; 2: neostigmine 5 yg/kg plus 4-aminopyridine 
150 pg/kg; 3: 4-aminopyridine 300 ug/kg; 4: edrophon-
ium 150 jg/kg; 5: edrophonium 150 yg/kg plus neostig-
mine 10 ug/kg; 6: edrophonium 150 Ug/kg plus 4-amino-
pyridine 150 ug/kg). 
d i sp lacement of a b locking agent from p o s t - f u n c t i o n a l r e c e p t o r s 
(Ar tus io e t a l . 1951; Randal l 1951), a d d i t i v e i n t e r a c t i o n with both 
neos t igmine and 4-aminopyr id ine i s t o be expec ted . Due t o the 
a n t a g o n i s t i c i n t e r a c t i o n we found, i t must be concluded t h a t e d r o -
phonium p o s s e s s e s a d i f f e r e n t , not y e t e x p l a i n e d , mechanism of 
a c t i o n whi le an t agon i z ing a pancuronium b lockade . The c e i l i n g 
e f f e c t m the dose response curve for edrophonium which we demon-
s t r a t e d (a l though we only s t u d i e d a few high doses of edrophonium), 
i s i n accordance wi th r e s u l t s found by o t h e r s . Seve ra l a u t h o r s 
found edrophonium to be inadequa te in r e v e r s i n g deeper d - t u b o c u r a r -
ine blockade both in man and in animals (Hunter 1952; Nastuk e t a l . 
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1954; Kupperman e t a l . 1 9 6 6 ; K a t z 1 9 6 7 ) . A l t h o u g h w i t h t h e c o m b i n ­
a t i o n o f n e o s t i g m i n e and 4 - a m i n o p y r i d i n e no a t r o p i n e was r e q u i r e d 
i n t h i s s t u d y , some a t r o p i n e was n e c e s s a r y t o k e e p a r t e r i a l p r e s s u r e 
a n d / o r h e a r t r a t e c o n s t a n t i n man ( M i l l e r e t a l . 1 9 7 9 ) . T h i s i n d i ­
c a t e s t h a t i t i s i m p o s s i b l e t o a b s o l u t e l y e x t r a p o l a t e t h e r e s u l t s 
f o u n d i n c a t s t o man. 
I n summary, we b e l i e v e t h a t , i n c o n t r a s t t o t h e c o m b i n a t i o n 
of n e o s t i g m i n e w i t h 4 - a m i n o p y r i d i n e , t h e c o m b i n a t i o n o f e d r o p h o n i u m 
a n d 4 - a m i n o p y r i d i n e i s c l i n i c a l l y of n o v a l u e f o r t h e a n t a g o n i s m o f 
a n o n d e p o l a r i z i n g n e u r o m u s c u l a r b l o c k a d e . 
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 DO N E O S T I G M I N E AND 4-AMINOPYRIDINE I N H I B I T T H E 
A N T I B A C T E R I A L ACTIVITY O F A N T I B I O T I C S ? 
L H D J BOOIJ, G С J VAN DER PLOEG, J F CRUL AND H L MUYTJENS 
S U M M A R Y 
Neostigmine and 4-aminopyridine are used to antagonize the neuromuscular blockade induced by 
antibiotics or an antibiotic-non-depolanzing blocker combination I hey may also counteract the 
antibacterial activity of antibiotics It uas found that neostigmine and 4-aminop\ ridine do not interfere 
with antibacterial acti\ it> οι antibiotics in bacterial cultures using an agar solution method It is concluded 
that neostigmine and í-ammop^ridmc ma> be used to antagonize ncuromusLular blockade induced bv 
antibiotics alone or in combination with non depolarizing agents 
The neuromuscular blocking effects of antibiotics 
and their interaction w ith neuromuscular blocking 
agents arc well known (Timmerman, Long and 
Pittinger, 1959, Pittinger and Adamson, 1972, 
Singh, Harvcv and Marshall, 1978) The resulting 
blockade is reversible in some cases by Cholines-
terase inhibitors or calcium
 vVan Nijhuis, Miller 
and Fogdall, 1976, Booii, Miller and Crul, 1978, 
Singh, Harvey and Marshall, 1978), depending on 
the antibiotic administered It has been demon-
strated that in most circumstances 4-aminopvri-
dine can reverse the neuromuscular blockade 
induced by antibiotic-myoneural blocker combi-
nation íBooij, Miller and Crul, 1978, Burkett et 
al , 1979) Antibiotics are administered more 
frequently in the operative period than previously 
and it is important to know whether reversing a 
blockade, induced or prolonged by antibiotics, 
with Cholinesterase inhibitors and 4-aminopv ri-
dine, influences the antibacterial effects of anti-
biotics In this studv we determined the effect of 
neostigmine and 4-aminopvridine on antibiotic-
treated bacterial cultures 
METHOD 
The minimal inhibitory concentration 'MIC) of 
antibiotics with and without addition of 4-amino-
pyridine or neostigmine or both, was determined 
with an agar dilution method The antibiotics 
studied were netilmvcin, gcntamicin, tobramycin, 
sisomycin, neomycin, lincomycin and clinda-
mycin 
1 FO Η Π J HOOIJ, M D , CTEHAHD ( J \AN DFR PlOEO, 4 D , 
PH D , JAN F С RLI , м η , HARRY 1 MUYTJENS, M D
 t 
Departments of Anesthesiology and Medical Microhiolog\, 
Catholic Lniversity, Nijmegen I he Netherlands 
(. orrespondencc to Dr L H D J BOOIJ, Department of 
Anesthesiology, С atholic Univcrsitv, M Radboud Hospital, 
Nijmegen, I he Netherlands 
I he antibiotics, 4-aminopyridine l O O n g m l ' 
and neostigmine 3 pg ml ' were mixed in the agar 
Fresh Muel ler-Hinton agar supplemented with 
5 % sheep blood or Schaedler agar, or both, were 
used for culture of aerobic and facultative 
anaerobic species D r u g solutions were added in a 
ratio of one part of drug solution to nine parts of 
medium, a control plate without drugs was in­
cluded T h e bacterial suspensions used were 6-h 
cultures of the individual strains tested in tryptone 
so\a broth diluted to a MacFarland 0 5 turbidity 
standard T h e agar plates were inoculated using a 
Denlev A 400 Mult ipoint Inoculator with ap­
proximately 1 3 x 1 0 * colony forming units on 
each spot Each agar plate was inoculated with 
three reference strains (A FCC or N C T C ) and 
with freshly isolated strains from patients Alter 
17 h incubation at 37 С the M I C was obtained 
'Barry, 1976) 
RESULTS 
I he bacterial strains on which the M I C was 
determined are summarized in table I 
Addition of 4-aminopyridine or neostigmine, or 
both, in concentrations of l O O n g m l ' and 
3 μg ml ' respectiveh, which are suggested to be 
peak plasma concentrations Cronnelly et al , 
1979, S Agoston, personal communication) did 
not alter M I C significantly (tables I I , I I I 
DISCUSSION 
Addition of neostigmine and 4-aminopyndinc to 
Schaedler and Mueller-Hinton agar to produce 
concentrations equal to the peak plasma concen­
tration after ι ν administration 'Cronnellv et al , 
1979, S Agoston, personal communication) did 
not influence the antibacterial activitv of anti­
biotics tested The administration of neostigmine 
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and 4-aminopyndine may be beneficial where 
neuromuscular blockade is caused by antibiotics 
or ihcir interactions with non-depolan/.ing 
neuromuscular blockers. Neostigmine and prob­
ably pyridostigmine enhance the blockade pro­
duced by aminoglycosides and should therefore be 
avoided (L. H. D. J. Booij and J. M. J. Ruttcn, 
unpblished data). Under these circumstances 4-
aminopyndine should be administered. NO central 
nervous system eifects occur with doses of 4-
aminopyndine up to 0.35 mg kg '. Higher doses, 
however, cause agitation and disorientation of the 
patient (Miller et al., 1979) and should not be used. 
It is concluded that neostigmine and 4-amino-
pyndine can be used to antagonize antibiotic-
induccd neuromuscular blockage without inter-
fenng with antibacterial activity. 
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LA NHOS'I IGMINI· ET L'AMINOPYRimNE-4 
I N H I B l N I - h L L h S L A C I IVITf·. AN I 1-
BAC lERIENNT. Dl-S ANFIBIOTIQUliS' 
On utilise la neostigmine ct raminopvridme-4 pour antago-
niser le blocage ncuromusculairc provoque par les anti­
biotiques ou par un melange bloquant antibiotique non de-
polansant hiles peuvent également reagir contre 1 activité anti-
bactenenne des antibiotiques On s'est aperçu que la neo-
stigmine et Гатіпоругк1іпе-4 ne troublent pas l'activité anti-
bactenenne des antibiotiques dans des cultures bactériennes 
pour lesquelles un a utilise la methode de la solution d'agar-
agar On en conclut qu'il est possible d'utiliser la neostigmine et 
78. 
1 aminopvndine-4 pour antagoniscr Ie blixage neuromus-
mlairc cause par les antibiotiques seuls on en melange avec deb 
agents non depolarisants 
BAKTLRIZIDL W I R K U N G VON A N I I B I O I I K A 
DURC H M Ob I ICïMINl U N D 4 -AMINOPYRIDIM 
Gl Н Ь М М І 5 
/LSAMMENfAiSLMj 
Neobngmine und 4-Aminopvridine werden zur Bckampíung 
der neuromuskulären Blockade verwendet, die durch 
Antibiotika oder eine Kombination von diesen mit mcht-de-
polansierendcn Blockierungsmitteln hervorgerufen wird bs 
ist auch möglich, dass sie der bakteriziden latigkcit von 
Antibiotika entgegenwirken I s wurde festgesteJit, dass 
Neostigmine und 4 Aminp\ndine keinen störenden Fintìuss 
auf die bakterizide I atigkeit von Antibiotika in 
Baktenenkulturcn ausüben, wenn eine Agarlosungsmethode 
verwendet wird bs wird geschlossen, dass Neosiigmini. und 4 
Ami nop\ ridine /UT Bekämpfung einer neuromuskulären 
Bltxkade verwendt werden können, die durch Antibiotika— 
entweder allein oder in einer Kombination mit nicht-de-
polarisierendcn Mitteln—hervorgerufen wurde 
INHIBÍ N I А ЛС FIVIDAD AN I I B A C Π RIA! D b 
I OS AN I IBIO I К Ob Ι Α Ν Κ ) - Ι S I I G M I N A Y LA 
A 4 I N O P I R I D I N A - 4 > 
SUMARIO 
Se usan la neo-estigmina ν la aminopindina'4 para antagoni7ar 
el bloqueo neuromuscular inducido por los antibióticos о рог 
una mezcla bloqucadora antibiotica no-üepolarizanre Pueden 
también reaccionar en contra de la actividad antibacterial de los 
antibióticos Se comprobo que la neo-estigmina y la 
aminopiridina-4 no imerhercn con la actividad aniibactcnal de 
los antibióticos en cultivos bacteriales cuando se uso el metodo 
de la solución de agar-agar Se llega a la conclusion de que se 
pueden unli/ar la neo-tstigmina y la aminopiridma-4 para 
antjgum¿ar el bloqueo neuromuscular inducido por los anti-
bióticos solos o en combinación con agentes no-depolanzantes 
79. 
"The design of panauvonium was an important step forward in 
medicinal chemistry and pharmacology, since it is one of few 
examples of success in the rational approach to drug design." 
- William C. Bowman (1980) 
Professor and Chairman of 
Physiology and Pharmacology, 
Univers i ty of S t ra thc lyde , 
Glasgow, Scotland. 
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CHAPTER 7 
CONCLUSIONS AND CLINICAL IMPLICATIONS 
Muscle relaxation during general anesthesia and intensive care 
treatment is requested to either facilitate intubation, facilitate 
artificial ventilation, or make surgery possible. At present, mus-
cle relaxation is achieved by the administration of specific muscle 
relaxing drugs. To date, pancuronium bromide is the most frequently-
used relaxant of the nondepolarizing type. Although it shows less 
severe side effects than the other nondepolanzers currently used, 
prolonged muscle relaxation and problems in reversibility of pancur-
onium were reported in the literature (Belafsky et al. 1974; Adams 
et al. 1975; Geha et al. 1976). Some of these adverse reactions 
could be explained from interaction with concomitantly administered 
drugs like anesthetics and antibiotics (chapter lì. Others could 
be explained from changes in the pharmacodynamic and pharmacokinetic 
behavior due to hypothermia, acid-base balance disturbances, and 
renal and/or hepatic failure (chapters 1 and 2). For some cases, 
no explanation was available. Since pancuronium is partially meta-
bolized in the liver, it was suggested that the metabolites are 
responsible for the remainder of the side effects. 
The metabolic pathways appeared to be deacetylation at the C3 
and C17 atoms of the pancuronium molecule, resulting in 3-OH-pancur-
onium, 17-OH-pancuronium, and 3,17-diOH-pancuronium derivatives. If 
these metabolites possess neuromuscular transmission blocking prop-
erties, they may contribute to the pancuronium-induced blockade. In 
circumstances of changed metabolism, they may therefore influence the 
degree, duration, and reversibility of such blockades as compared 
with normal circumstances, and hence could be the origin of prolonged 
blockade and irreversibility. Changes in body temperature, induction 
or inhibition of liver enzymes, or hepatic diseases may, as occurs 
with many other drugs, cause a changed metabolism. We demonstrated 
(chapters 3, 4, and 5) that all metabolites possess neuromuscular 
blocking properties, pancuronium being twice as potent as 3-OH-pan-
curonium, and 40 to 50 times as potent as 17-OH-pancuronium or 3,17-
diOH-pancuronium. 
Due to this potency and the estimated amount produced, only 
3-OH-pancuronium can be considered as contributing to the pancuronium 
blockade to a clinically important extent (chapter 4). This contri-
bution may be even larger if 3-OH-pancuronium were to interact syner-
gistically with pancuronium or behave pharmacodynamically and pharma-
cokinetically in a different way. Because of their individual po-
tencies and the amount to which they are produced, 17-OH-pancuronium 
and 3,17-diOH-pancuronium would only be of clinical importance if 
they interacted synergistically with pancuronium. We demonstrated 
that the metabolites in man do not behave differently from pancuron-
ium either pharmacodynamically or pharmacokinetically (chapter 4). 
In the in vitro and in vivo animal studies we performed, a synergis-
tic interaction could not be demonstrated. In the in vitro experi-
ments only summative (additive) interaction was present, whereas in 
the in vivo experiments only an antagonistic effect of the metabol-
ites on pancuronium was seen (chapter 5). An explanation for this 
discrepancy could not be proposed. As the interaction seems to be 
antagonistic, this cannot therefore cause a prolongation of the pan-
curonium blockade. 
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In view of significant species differences, it is impossible 
to predict the pharmacodynamic behavior of nondepolarizing relaxants 
in man from animal studies. Since an indication of the potency and 
the duration of action is necessary before studies in man can safely 
be performed in patients, we looked for a method to obtain such an 
indication. The isolated arm technique (chapter 3) proved to be a 
reliable method to predict the potency and duration of action (i.e. 
the pharmacodynamics) of relaxants in volunteers without causing 
interference with respiration and psychomotor functions of the 
volunteer (chapter 3). The pharmacodynamic results we obtained for 
pancuronium and its metabolites with the isolated arm technique 
were substantiated by the results obtained in patients with the same 
compounds (chapter 3.2). As mentioned above, significant differences 
between pancuronium and its metabolites in onset of action, duration, 
and recovery could not be demonstrated, with the exception that 17-
OH-pancuronium had a shorter duration of action in patients (chapter 
4) . 
We therefore conclude that the pancuronium metabolites do not 
pharmacodynamically behave differently from pancuronium. 
It has been shown by others that the degree of the existing 
blockade correlates well with the plasma concentration of pancuronium 
after intravenous administration (Agoston et al. 1979; Shanks et al. 
1979) . This indicates a clear correlation between pharmacodynamics 
and pharmacokinetics. It is therefore not surprising that the pharma-
cokinetics of the metabolites of pancuronium do not differ, either 
(chapter 4). 
It must be concluded that prolonged duration of action is more 
likely due to absolute or relative overdose of pancuronium, disturb-
ances in liver uptake or renal excretion, or possible interaction 
with concomitantly administered drugs (antibiotics and/or anesthe-
tics) . The metabolites of pancuronium do not play a significant 
role. 
Problems are also described with reversibility of pancuronium 
blockade. In some cases the blockade cannot be reversed, while m 
other cases reversal is accompanied by many muscarinic side effects 
(chapter 6.1). Especially when other factors like acidosis, hypo-
thermia, and drug interactions are excluded, the pancuronium meta-
bolites were blamed. We therefore undertook to determine whether 
neostigmine can equally reverse blockade by pancuronium and its 
metabolites. 3-OH-pancuronium needed less neostigmine than pancur-
onium, whereas 17-OH-pancuronium and 3,17-diOH-pancuronium needed 
more neostigmine (chapter 6.3), and blockade by any of these could 
be completely reversed. Since 17-OH-pancuronium and 3,17-diOH-pan-
curonium are only present in small amounts, and are not very potent, 
a significant degree of blockade due to these compounds will not 
occur. Thus, dosages of neostigmine that normally reverse the pure 
pancuronium part of the blockade will also be sufficient to reverse 
the metabolite-induced partial blockades, such that they do occur. 
Failure of reversal of pancuronium blockades therefore remain the 
result of other factors as mentioned above, including the adminis-
tration of insufficient amounts of Cholinesterase inhibitors. 
Large amounts of Cholinesterase inhibitors cause severe mus-
carinic side effects. Administration of high dosages of pyndostig-
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mine or neostigmine is thus undesirable. Since it is thought that 
the main effect of these compounds m reversing curanform blockade 
is the availability of increased amounts of acetylcholine at the 
motor end-plate, other drugs resulting in increased synaptic acetyl­
choline production may be useful. The combined administration of 
neostigmine or pyridostigmine with such a drug may be advantageous 
and diminish the muscarinic side effects. For this reason, 4-amino-
pyridine, an acetylcholine release-facilitating compound, was com­
bined with neostigmine or pyridostigmine. A synergistic interaction 
was demonstrated (chapter 6.5 and 6.6). This has led to a consider­
able decrease in the amount of neostigmine or pyridostigmine needed 
(chapter 6.6), and, indeed, resulted in less severe or even absent 
muscarinic side effects. From our studies it can also be concluded 
that edrophonium has a mechanism of action different from neostig­
mine or pyridostigmine because it is antagonized by both neostigmine 
and 4-aminopyridine (chapter 6.7). Concomitant or subsequent admin­
istration of edrophonium with 4-aminopyridine or neostigmine should 
therefore be avoided. 
When antibiotics enhance nondepolarizing neuromuscular blockades 
or cause blockades by themselves, neostigmine and/or 4-aminopyridine 
are frequently administered in an attempt to reverse such blockades. 
When reversal is successful, the antibacterial activity of the anti­
biotic may also be antagonized, which is, of course, undesirable. 
In bacterial cultures we therefore studied the possibility of such 
an antagonism by determining minimal inhibiting concentrations of 
antibiotics with and without neostigmine and/or 4-aminopyridine. 
Neither neostigmine nor 4-aminopyridine antagonized the antibacterial 
activity of the antibiotics we studied (chapter 6.8). 
Due to its many effects (chapter 6.2), it is not recommended 
that 4-aminopyridine be administered alone, although its combined 
administration with neostigmine or pyridostigmine can perhaps be 
advantageous. 
In conclusion, it can be stated that the role of the metabolites 
of pancuronium is of minor importance m the determination of the 
degreee, duration, and antagonism of a pancuronium neuromuscular 
blockade. 
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"It should be remembered, hauever, that the use of relaxants constitutes a 
deliberate encroachment on one of the most important physiological mechanisms, 
respiration. Every instance of their application should be looked upon as an 
experiment in applied pharmacology." 
- Francis F. Foldes (1967) 
Emeritus Professor of Anesthesia, 
Montefiore Hospital and 
Albert Einstein University, 
New York, U.S.A. 
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CHAPTER 8 
SUMMARY 
Pancuronium is currently the most frequently-used nondepolar-
izing muscle relaxant. Compared to the other clinically available 
nondepolarizers, its side effects are less severe. It is metabol-
ized in the liver, and excreted mainly m the urine. 
The rate and extent of metabolism are not precisely known, due 
to the present lack of a specific quantitative method of determina-
tion in biological fluids. Based on aspecific semiquantitative 
methods, the metabolism is assumed to be 30 to 45 % of the dose 
administered. 25 to 35 % is transformed into 3-OH-pancuronium, and 
50 to 10% into 17-OH-pancuronium and 3,17-diOH-pancuronium together. 
As demonstrated in chapters 3, 4, 5, and 6, all derivatives result 
in neuromuscular blocking activity, and may thus contribute to a 
pancuronium neuromuscular blockade. Their potency ratios compared 
to pancuronium are: only 1/2 for 3-OH-pancuronium, and 1/40 to 
1/50 for 17-OH-pancuronium and 3,17-diOH-pancuronium. Based on the 
assumed extent of metabolism and their potencies, only 3-OH-pancur-
onium is capable of contributing to a pancuronium neuromuscular 
blockade, provided the other derivatives do not interact in a poten-
tiating manner. As demonstrated in chapter 6, such an interaction 
does not exist. Since 3-OH-pancuronium, like the other metabolites, 
does not behave pharmacokmetically differtly from pancuronium, 
this derivative also seems to be of no significant clinical impor-
tance. 
Only if a large amount of 3-OH-pancuronium, or a significant 
quantity of pancuronium, accumulates in the body (renal failure), 
can a prolonged duration of action be expected. In the case of 
hepatic disease, metabolism of pancuronium may be diminished, and 
the plasma level hence elevated for a longer period of time. These 
are the only currently available explanations for the prolonged 
duration of action, aside from interaction with other drugs (chapter 
1). The metabolites of pancuronium by themselves are thus clinical-
ly insignificant. 
Antagonism of pancuronium may be necessary. When the anti-
cholinesterases are used, major muscarinic side effects can be seen, 
depending on the dose administered. Small amounts of 4-aminopyri-
dine synergistically potentiate neostigmine and pyridostigmine, 
thereby decreasing the amount needed (chapter 7). Edrophonium is 
different, however. It is antagonized by both neostigmine and 4-
aminopyndine. A different mechanism of action for edrophonium 
compared to neostigmine and pyridostigmine seems to exist. Neo-
stigmine can antagonize the action of both pancuronium and its 
metabolites completely. Moreover, less neostigmine is needed to 
antagonize a 3-OH-pancuronium blockade (chapter 6). If this com-
pound would contribute to the pancuronium blockade, no difficulties 
with reversing the paralysis would be expected. 17-OH-pancuronium 
and 3,17-diOH-pancuronium require more neostigmine, but are pro-
duced in such small quantities that when sufficient amounts of 
antagonists are administered to reverse pancuronium, no problems 
exist. Incomplete reversal is thus not due to the metabolites of 
pancuronium. Especially 4-aminopyridine is active when an anti-
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biotic-induced neuromuscular blockade exists. It is therefore pre-
ferable in combined antibiotic-nondepolarizer blockades. The anti-
bacterial activity of the antibiotic is then not affected by 4-
aminopyridine or neostigmine (chapter 6). 
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SAMENVATTING 
Momenteel is pancuronium het meest gebruikte niet-depolanzerende 
spierrelaxans. Vergeleken met andere klinisch gebruikte niet-
depolanzerende relaxantia heeft het de minst ernstige bijwerkingen. 
Het wordt in de lever gemetaboliseerd en voornamelijk via de urine 
uitgescheiden. Snelheid en mate van metabolisme zijn niet exact 
bekend omdat een specifieke kwantitatieve bepalingsmethode m bio-
logische vloeistoffen ontbreekt. Gebaseerd op aspecifieke semi-
kwantitatieve methoden wordt verondersteld dat het metabolisme 30 
tot 45 procent van de toegediende hoeveelheid bedraagt. Daarbij 
wordt 25 tot 35 procent omgezet in 3-OH-pancuronium en 5 tot 10 
procent in 17-OH-pancuronium en 3,17-diOH-pancuronium tesamen. 
Zoals in de hoofdstukken 3,4,5 en 6 wordt aangetoond hebben alle 
derivaten neuromusculaire overdracht blokkerende eigenschappen, en 
kunnen derhalve bijdragen aan een door pancuronium geïnduceerde 
blokkade. De effect ratios zijn vergeleken met pancuronium: slechts 
k voor 3-OH-pancuroniam en 1/40 tot 1/50 voor 17-OH-pancuronium en 
3,17-diOH-pancuronium. Gebaseerd op de veronderstelde mate van 
metabolisme en de effectiviteiten wordt alleen van 3-OH-pnacuronium 
aangenomen dat het een bijdrage aan een door pancuronium veroor-
zaakte neuromusculaire blokkade kan leveren. Hierbij wordt aan-
genomen dat er geen potentierende wisselwerking tussen de meta-
bolieten bestaat. Zoals wordt aangetoond in hoofdstuk 6 treedt 
een dergelijke wisselwerking niet op. Omdat 3-OH-pancuronium zich, 
evenals de andere metabolieten, farmacokinetisch niet verschillend 
gedraagt ten opzichte van pancuronium, lijkt ook deze afgeleidde 
niet van klinische betekenis te zijn. Alleen als een grote 
hoeveelheid 3-OH-pancuronium of een significante hoeveelheid pancu-
ronium in het lichaam ophoopt (niennsufficientie) kan een 
verlengde werkingsduur worden verwacht. In het geval van lever-
ziekten zou de afbraak van pancuronium verminderd kunnen zijn, 
en de plasma concentratie dus voor een langere tijd hoog blijven. 
Op dit moment vormen dit de enige verklaringen voor verlengde 
werkinsduur naast interactie met andere farmaca (Hoofdstuk 1). 
Klinisch zijn de metabolieten van pancuronium daarom van geen 
belang. 
Soms is het nodig om pancuronium te antagoneren. Indien daarvoor 
acetylcholinesterase remmers worden gebruikt, dan kunnen, afhanke-
lijk van de toegediende hoeveelheden, ernstige muscarine bijwerk-
ingen optreden. Kleine hoeveelheden 4-aminopyridine versterken 
de werking van neostigmine en pyridostigmine. Hierdoor wordt 
de benodigde hoeveelheid verminderd (Hoofdstuk 6). Edrophonium 
gedraagt zich echter anders. Het wordt zowel door neostigmine 
als door 4-aminopyridine tegengewerkt. Hierdoor lijkt de aanname 
van een ander werkingsmechanisme voor edrophonium in vergelijking 
met neostigmine en pyridostigmine gerecitvaardigd. Neostigmine is 
in staat de werking van zowel pancuronium als haar metabolieten 
op te heffen. Om een 3-OH-pancuronium blokkade op te heffen is 
zelfs minder neostigmine nodig. Indien deze stof mocht bijdragen 
aan een pancuronium blok, zijn er geen problemen bij het antagon-
eren van de verslapping te verwachten. 17-OH-pancuronium en 3,17-
diOH-pancuromum behoeven meer neostigmine, maar worden in dusdanig 
kleine hoeveelheden gevormd dat indien voldoende grote hoeveelheden 
antagonist worden toegediend om de pancuronium te antagoneren, geen 
problemen zullen ontstaan. Onvolledig antagonisme is derhalve niet 
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het gevolg van de metabolieten van pancuronium. Vooral 4-aminopyri-
dxne is ook actief indien een door antibiotica geïnduceerde neuro-
musculaire blokkade bestaat. Het verdient dan ook de voorkeur 
bi] een gecombineerde antibiotica - niet depolanzend relaxans 
blokkade. De anti-bacteriele werking van de antibiotica wordt daar-
bi] noch door 4-aminopyridine noch door neostigmine aangetast 
(Hoofdstuk 6). 
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STELLINGEN 
I 
Scientific development of anesthesia in The Netherlands is inhibited by 
emphasis on clinical work over research in the academic anesthesia 
departments. 
De wetenschappelijke ontwikkeling van de anesthesiologie in Nederland 
wordt geremd door een te sterke overheersing van het klinische werk in de 
academische anesthesie afdelingen. 
II 
That nondepolarizing muscle relaxants can act specifically on the motor 
end-plate has been demonstrated by the development of Norcuron 
Dat niet depolarizerende spier relaxantia zeer specifiek op de motor-eind-
plaat kunnen werken is gedemonstreerd aan de ontwikkeling van Norcuron. 
I G Marshall, S Agoston, L H D J Booij, 
N N Durant and F F Foldes Br J Anaesth 52 11-20S, 1980 
III 
Hypothermia exerts an effect on nondepolarizing neuromuscular blockade 
opposite to the effect usually described in the literature. 
Hypothermie heeft een effect op de met depolarizerende zenuwspier blok­
kade welke tegenover gesteld is aan die welke in de literatuur meestal wordt 
gevonden. 
W С Bowman pharmacology of neuromuscular function 
pp 108-109, Wright & Sons Ltd Bristol 1980 
IV 
Increased calcium release in skeletal muscle cells is not the origin, but a 
result, of malignant hyperthermia. 
Toegenomen calcium vrijmaking in skeletspiercellen is niet de oorzaak, maar 
een gevolg van maligne hyperthermic. 
Τ E Nelson and E Η Flewellen 
Texas reports on Biol and Med 38 105-120, 1979 
ν 
The development of clean, short-acting anesthetic drugs is obligatory to 
make total intravenous anesthesia safe and acceptable. 
De ontwikkeling van kort werkende anesthesie farmaca zonder bijwerkingen 
is voorwaarde om een volledige intraveneuze anesthesie techniek veilig en 
aanvaardbaar te maken. 
T. M. Savege, M. A. E. Ramsay, J. P. J. Curran, J. Cottes, 
P. T. Walling and В. R. Simpson. Anaesthesia 30: 757-764, 1975. 
VI 
From a scientific viewpoint, routine epidural application of morphino-
mimetics for pain relief is premature. 
Uit wetenschappelijk oogpunt is de routine-matige epidurale toediening voor 
pijn bestrijding nog voorbarig. 
F. Magora, D. Olshwang, D. Eimerl, J. Shorr, R. Katrenelson, 
S. Cotev and J. T. Davidson. Br. J. Anaesth. 52: 247-252, 1980. 
VII 
Regionalization and concentration of traumatology and major emergency 
care is necessary for reasons of treatment efficiency and economy. 
Regionalisatie en concentratie van de traumatologie en grotere eerste hulp 
is noodzakelijk om redenen van effectiviteit van behandeling en kosten 
bewaking. 
VIII 
The clinical use of 4-aminopyridine will be limited by the multitude of 
pharmacological effects. 
Het klinisch gebruik van 4-aminopyridine zal beperkt zijn door de veelheid 
van haar farmacologische effecten. 
This Thesis, Chapter 6.2. 
IX 
When a new drug with less severe as well as fewer side effects is registered, 
its predecessors with more side effects should be withdrawn from the market. 
Als een nieuw geneesmiddel met minder en geringere bijwerkingen is ge­
registreerd, zouden zijn voorgangers met meer bijwerkingen uit de markt 
moeten worden genomen. 
χ 
The application of stricter ethical norms will decrease the cost of the present 
"sophisticated advanced" medical care. 
De toepassing van strengere ethische normen zal de kosten van de huidige 
"sophisticated advanced" medical care doen dalen. 
XI 
The problem of the empty stomach in anesthesia needs a sober approach. 
Het probleem van de nuchterheid in de anesthesie behoeft een nuchtere aan­
pak. 
C. D. Blitt, H. L. Gutman, D. D. Cohen, H. Weisman 
and J. B. Dillon, Anesth. Anaig. 49: 707-713, 1970. 
XII 
On many occasions disputes between surgeons and anesthetics are induced 
and solved by the plasma potassium level of the patient. 
Vaak worden meningsverschillen tussen chirurgen en anesthesisten op­
geroepen of opgelost door een afwijkende plasma kalium concentratie van 
de patient. 
XIII 
The verdict "Everyone knows better, although no one really knows it well" 
is reflected in the many committees existing today. 
Het gezegde "Iedereen weet het beter, doch niemand weet het goed" wordt 
weerspiegeld in de vele commissies welke thans bestaan. 


